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Oxygen is a key parameter in maintaining cell viability and functionality.  This is 
especially true in encapsulated cell systems, as the cells within the constructs rely solely 
on diffusion for the transport of dissolved oxygen.  Furthermore, many poorly known in 
vivo factors influencing construct oxygenation strongly affect the implant’s therapeutic 
function.  However, construct function is only assessed based on end physiologic effects 
or post-explantation studies at which an animal is euthanized.  In order to develop a long-
term functional implant, finding a means to enhance and monitor construct oxygenation 
in vivo is crucial.  In this regard, perfluorocarbons (PFCs) can be utilized as an oxygen 
carrier, due to its high capacity for dissolving oxygen, to potentially improve the survival 
and function of encapsulated cells.  Besides that, PFCs also serve as oxygen 
concentration markers for 19F Nuclear Magnetic Resonance (NMR), whereby this method 
can be used to noninvasively track the oxygenation state of cells in a construct in vitro 
and in vivo.   
The addition of a PFC emulsion improves the overall construct oxygenation by 
increasing the effective diffusivity of dissolved oxygen into the constructs.  Whether this 
enhancement is sufficient to significantly improve cell viability and function is still a 
subject of debate, as there have been conflicting reports in literature regarding the 
beneficial effects of PFCs.   The work in this thesis investigated this question as it relates 
to encapsulated cell systems.  Perfluorotributylamine (PFTBA) emulsion was co-
encapsulated at 10 vol% with βTC-tet cells in alginate beads and the cell/PFC constructs 
were cultured under normoxic and severely hypoxic conditions in the long- and short-
 xiv
term.    The alginate-PFC-cell system was also modeled mathematically, and simulations 
tracked dissolved oxygen concentration (DO) and the number of viable cells within the 
constructs over time under the same conditions used experimentally.   Experimental 
results showed no significant improvement in cell metabolic activity, viability, and 
insulin secretory function with the addition of PFTBA.   This finding was consistent with 
the results of mathematical simulations that noted only a small, likely experimentally 
undetectable, increase in cell density in PFC-containing beads.  Simulations also 
indicated an increased positive effect of PFC on cells with a higher oxygen consumption 
and growth rates, but this was also modest in magnitude.    
Besides having a high solubility of oxygen, the high fluorine content of PFCs 
makes them good oxygen concentration markers for 19F NMR.  As the relaxation rates 
(R1 = 1/T1) of excited fluorine nuclei increase in the presence of oxygen, DO within an 
implant can be measured through 19F NMR when PFCs are incorporated.   The ability to 
noninvasively monitor DO allows for an assessment of the metabolic activity of the cells 
within the construct, and for important correlations to be established between these in 
vivo measurements and construct function.  The work in the second part of this thesis 
involved the development of a dual PFC noninvasive method of monitoring DO in a 
tissue engineered pancreatic construct using 19F NMR.   The dual PFC method consists of 
the incorporation of each of two different PFCs with proximal chemical shifts, either in 
the experimental tissue implant (βTC-tet cells encapsulated in alginate beads) or in cell-
free alginate beads; the cell-free beads are used to monitor DO in the surrounding 
medium or implantation milieu, as equilibration of the intrabead and external DO is 
assumed to be rapid.   
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The feasibility of this method was tested in vitro where the encapsulated cells 
were cultured under perfused and static conditions in an NMR-compatible bioreactor.  T1 
relaxation measurements were acquired over time at different encapsulated cell densities.  
Using this method, T1 relaxations within the cell-containing beads and cell-free beads can 
be obtained simultaneously; therefore DO within the constructs containing metabolically 
active cells can be measured relative to the surrounding medium.  Steady-state DO 
measurements acquired under medium perfusion showed minimal DO difference between 
the cell-containing beads and the surrounding medium; a considerable difference was 
only detected at a high encapsulated cell density of 7×107 cells/ml.   Under static 
conditions, however, significantly lower DO levels were measured within the cell-
containing beads when compared to the surrounding medium, which demonstrated the 
capability of the method to track the oxygenation state of beads containing metabolically 
active cells.   The DO profiles obtained under static conditions were also supported by 
mathematical simulations of the system, indicating that the observed trends were not 
measurement artifacts. 
 The dual PFC method of monitoring was implemented in vivo using murine 
models.  The βTC-tet cell-containing alginate beads were implanted in the peritoneal 
cavity of normal and streptozotocin-induced diabetic mice.  Cell-free alginate beads were 
co-implanted to track the DO in the implantation milieu.  T1 measurements were acquired 
from the two bead populations over time, and construct physiology and therapeutic 
function were assessed through post-explantation studies and blood glucose 
measurements, respectively.  Through 19F NMR, the capability of acquiring real-time in 
vivo DO measurements using the dual PFC method was demonstrated.  In both normal 
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and diabetic mice, measurements showed the peritoneal environment to be hypoxic and 
variable.  DO within cell-containing beads decreased over time and correlated with 
relative changes in the number of viable encapsulated cells and/or the extent of host cell 
attachment.  The presence of the viable cell implant also caused a significant decrease in 
the surrounding peritoneal DO.  Diabetic mice receiving βTC-tet cell constructs remained 
normoglycemic for the duration of the experiment; the reduction in construct DO due to 
the metabolic activity of the encapsulated cells was observed to be compatible with the 
implant therapeutic function.  
 In conclusion, the work in this thesis demonstrated the limited beneficial effect of 
PFC in encapsulated cell systems.  A noninvasive 19F NMR method of monitoring the 
functional state of a tissue engineered pancreatic construct was also developed.   The 
established method allowed for the evaluation of the oxygen environment in the animals, 











In the United States alone, approximately 1.8 million people are diagnosed with 
type 1 diabetes [1].  The majority of diabetic patients currently rely on exogenous insulin, 
delivered through daily injections or pumps, to normalize their blood glucose.  However, 
even with vigorous insulin therapy, a tight regulation of blood glucose cannot be 
achieved, therefore leading to long-term complications of the disease [2].  Cell-based 
therapies such as pancreas and islet cell transplantation emerged to be promising 
treatment alternatives as the physiological secretion of insulin by the cells provides for a 
better glucose regulation.  While a reduction in glycemic fluctuations and improvement 
in the quality of life have been observed, there still exist challenges preventing the 
success of these treatments.  Transplant recipients are required to take 
immunosuppressive drugs for the rest of their lives to avoid organ or cell rejection, and 
transplantation is limited by the scarcity of human donors [3].  
Many studies have been and are currently focused on developing tissue 
engineered pancreatic constructs (TEPCs) to alleviate the issues associated with these 
therapies.   The use of alternative cell sources such as xenogeneic islet cells and 
genetically-engineered β or non- β cells are being investigated [4-6].  These cells are 
entrapped in a 3-dimensional, biocompatible material for protection from the host 
immune system.  Such a construct is an insulin reservoir of infinite capacity and is 
capable of regulating insulin delivery continuously as long as the cells remain viable.  A 
significant concern, however, is the delivery of oxygen into the construct, as oxygen is 
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usually the limiting nutrient in maintaining cell viability and function.  The encapsulated 
cells might be subjected to transient hypoxia, as a result of construct handling, or to 
constant hypoxia, due to the hypoxic in vivo environment and the absence of 
vascularization around the constructs [7, 8].  Furthermore, many other poorly known 
factors that affect construct oxygenation, thus cell function in vivo often lead to implant 
failure, and can be detected only based on end physiologic effects [9].  An understanding 
of the mechanisms of implant failure and early detection will aid the development of an 
optimum construct design and increase safety if implanted in patients. Therefore, finding 
a way to enhance oxygen delivery and to noninvasively monitor the functional state of a 
TEPC would be invaluable. 
Perfluorocarbons (PFCs) are unique nontoxic compounds that have a high 
capacity for dissolving oxygen [10] and have been used for many years as oxygen 
carriers [11, 12].  As it has also been shown that the 19F Nuclear Magnetic Resonance 
(NMR) spin-lattice relaxation rates of PFCs are highly sensitive to oxygen, there has been 
developing interest in using these compounds to probe tissue physiology [13, 14].  The 
overall goal of this thesis was to investigate the use of PFCs in improving cell viability 
and function in a TEPC, and to develop a method to noninvasively monitor the functional 
state of a TEPC in vitro and in vivo, through 19F NMR.   For the latter, the objective was 
to establish a method to measure the dissolved oxygen concentration (DO) that the cells 
experience in the constructs, and to draw correlations between construct oxygenation and 
cell viability and function.  This goal was achieved by completing the following specific 
aims:  
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Specific Aim 1: Investigate the effects of PFCs on the viability and function of 
encapsulated cells under normoxic and hypoxic conditions. 
Specific Aim 2:  Establish and validate the feasibility of a dual PFC method of 
monitoring DO within a TEPC in vitro through 19F NMR. 
Specific Aim 3: Implement the dual PFC method to monitor DO within a TEPC in vivo 
through 19F NMR. 
In this thesis work, the TEPC employed for both in vitro and in vivo studies 








Figure 1.1 Configuration of the TEPC used.   
PFCs were incorporated in the form of an emulsion, with the droplets immobilized and 
homogeneously dispersed throughout the alginate matrix.  The cells were only present in 
the aqueous phase of the construct.  Oxygen does not bind chemically to the PFC, but it 
dissolves and equilibrates between the PFC and aqueous phase with a partition coefficient 
favoring the PFC phase.  Two types of beads were studied; calcium alginate-poly-L-













CHAPTER 2 of this thesis provides the details of the TEPC, and the background of the 
different applications of PFCs in such constructs and in other biological systems.   
As oxygen availability affects cell function and limits the number of cells that can 
be supported by a construct, researchers are constantly investigating methods to enhance 
construct oxygenation.  The use of PFCs is an appealing approach as these compounds 
have the ability to dissolve approximately 10 to 20 times more oxygen than water [10].  
In tissue constructs where the PFC is not convectively transported, the PFC phase can act 
as an oxygen carrier by improving the overall construct oxygenation through the increase 
in the oxygen effective diffusivity, or as a transient oxygen reservoir by releasing oxygen 
to the aqueous phase under hypoxic conditions.  The incorporation of PFCs, whether in 
the form of pure liquid or an emulsion, has been shown to increase oxygenation and 
hence improve cell viability and function in different tissues [15-17].  Despite 
encouraging results however, there are studies that show the contrary [18-20].  The 
benefits are still unclear as the significance of the PFC effect is likely dependent on each 
system, such as the cell type used, the concentration of PFC incorporated, and the 
external oxygen conditions.   In CHAPTER 3 of this thesis, we investigated this question 
specifically to applications with encapsulated insulin-secreting cells.  We studied 
experimentally the effect of a PFC emulsion, perfluorotributylamine (PFTBA), on the 
metabolic activity, viability, and insulin secretory function of βTC-tet insulinoma cells 
encapsulated in calcium alginate beads under normoxic and hypoxic conditions.  A 
mathematical model of the alginate-PFC-cell system was also constructed under both of 
these conditions and simulation results were compared to those obtained experimentally.  
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 Besides enhancing oxygen delivery, PFCs have been used as oxygen 
concentration markers for 19F NMR to probe tissue oxygenation.   DO within a tissue 
engineered construct is a significant parameter to be measured due to the high 
dependence of cell survival and function on oxygen.  The presence of oxygen, which is 
paramagnetic, causes the spins of excited fluorine nuclei from the PFCs to relax faster. A 
linear relationship exists between the inverse spin-lattice relaxation time (1/T1) of the 
fluorine resonances and oxygen, enabling the determination of DO when PFCs are 
incorporated into the constructs. The advantage of the 19F nucleus is its absence in most 
biological tissues, thus eliminating the problem of interfering background signals.  
Furthermore, its high sensitivity enables T1 acquisitions even at low concentrations of 
PFCs.  We developed a dual PFC method (Figure 1.2) capable of tracking DO within a 
tissue implant and in its surroundings.  The latter measurement is important as the in vivo 
oxygen environment can vary significantly over time and among animals.   
                                                                          



















The dual PFC method consists of the incorporation of each of two different PFCs 
with proximal chemical shifts, either in the experimental tissue implant (βTC-tet cells 
encapsulated in alginate beads) or in cell-free alginate beads.  The cell-free beads are 
used to monitor DO in the surrounding medium or implantation milieu, as equilibration 
of the intrabead and external DO is assumed to be rapid.  In this work, the two PFCs 
used, perfluorotributylamine (PFTBA) and perfluoro-15-crown-5-ether (PFCE), have 
chemical shifts 9 ppm apart, close enough to allow for simultaneous T1 acquisitions.   
Our approach in this 19F NMR monitoring method is to acquire a single DO from the 
entire construct representing a volume average measurement of oxygen concentrations 
within the volume of interest.   
The feasibility of the monitoring method was tested in vitro by culturing the dual 
PFC bead population in an NMR-compatible bioreactor.  The work, as reported in 
CHAPTER 4 of this thesis, was done to demonstrate that (1) DO measurements in the 
two groups of beads can be simultaneously obtained through 19F NMR, and (2) the DO 
level in beads with encapsulated cells can be distinguished from the DO level in beads 
without cells, where the latter is equal to the DO in the surrounding medium.  DO 
differences between these two groups of beads were assessed under perfused and static 
culturing conditions.  The DO profiles under static culturing conditions were also 
simulated using a mathematical model of the system and compared to the experimental 
results.  
Following in vitro feasibility studies, the dual PFC method was implemented in 
vivo using murine models.  The function of an implanted TEPC is influenced by many 
poorly known in vivo factors; however, the assessment of construct function is solely 
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based on the observed end physiologic effects.  The development of the dual FPC method 
of monitoring will aid in the understanding of implant function through correlations 
established between in vivo DO measurements and both the construct physiology and 
therapeutic function, assessed through post-explantation studies and blood glucose 
measurements, respectively.   CHAPTER 5 of this thesis reports on the implementation 
of the dual PFC method in vivo, in normal mice (Part I) and in diabetic mice (Part II).  In 
Part I of chapter 5, we investigated the feasibility of acquiring in vivo DO measurements 
in the dual PFC bead population using 19F NMR, and established correlations between the 
measured construct DO with cell growth and host cell attachment examined post-
explantation.  In Part II of this chapter, in addition to examining construct physiology, 
construct therapeutic function was assessed through blood glucose measurements and 
correlated to the measured construct DO.  Real-time DO measurements were obtained in 
functional and non-functional constructs implanted in both normal and streptozotocin-
induced diabetic mice. The usefulness of the information provided by these studies on the 
in vivo functionality of the cell implants, and on the effect of such implants on host 
animal physiology, is discussed. 
Finally, the conclusions drawn from these studies are summarized in CHAPTER 6 
of this thesis.  The potential and research directions of the dual PFC method are also 
discussed. 







2.1  Diabetes 
There is an increasing prevalence of diabetes worldwide.  According to the 
Centers for Disease Control and Prevention, a total of 23.6 million people in the United 
States alone suffer from this disease, with medical costs totaling to approximately $174 
billion in 2007 [1]. Type 1 diabetes, formerly known as insulin-dependent diabetes 
mellitus, accounts for 5% to 10% of all diagnosed cases of diabetes [1].  This disease 
develops when the body’s immune system destroys the β cells of the pancreatic islets, the 
only cells in the body that produce insulin to regulate blood glucose.  Thus type I diabetic 
patients depend upon exogenous insulin therapy for life [3].  On the other hand, type 2 
diabetes, formerly known as non-insulin-dependent diabetes mellitus, accounts for 90% 
to 95% of all diagnosed cases of diabetes [1].   It is a milder form of diabetes which 
occurs when the pancreas loses its ability to produce insulin or when the body is resistant 
to the action of insulin produced.  While oral medication, exercise, and diet are usually 
sufficient to temporarily stabilize blood glucose levels, type 2 diabetes usually develops 
into insulin-dependence [3, 21].   
Insulin deficiency or resistance results in an increase in blood glucose levels; 
diabetes is diagnosed when the fasting or non-fasting plasma glucose is ≥ 7.0 mmol/l 
(126 mg/dl) and ≥11.1 mmol/l (200 mg/dl), respectively [22].  It is associated with 
unusual thirst, frequent urination, weight loss, extreme fatigue and can sometimes lead to 
coma.   Diabetics have an increased susceptibility to infections and are prone to develop 
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vascular complications such as stroke, heart attack, blindness, renal failure, and 
peripheral nerve damage.  One proposed mechanism which has been postulated to play a 
central role in vascular complications is the process of advanced glycation.  This process 
involves the generation of advanced glycated end products (AGEs) as a result of glucose 
interacting with the amine residues on proteins, lipids, and nucleic acids.  The cross-
linking of AGE with type I collagen and elastin leads to increased stiffness of blood 
vessels, which eventually causes tissue and organ damage [23, 24].  Diabetes therapy 
aims to normalize glucose control without introducing severe hypoglycemic episodes [2] 
as low blood glucose levels result in dizziness, weakness, heart palpitation, anxiousness, 
and tremor among others.  If blood glucose levels continue to fall, neurologic 
manifestations can occur, which cause loss of consciousness, convulsion, and deep coma.  
Prolonged severe hypoglycemia may even lead to brain damage [24].  
 
2.1  Current Type 1 Diabetes Treatment Methods 
The discussion focuses on the treatment methods for type 1 diabetics; however, 
most of these considerations apply to insulin-dependent type 2 diabetics as well.  Type 1 
diabetes is treated with insulin replacement therapy where exogenous insulin is delivered 
subcutaneously by injections or an insulin pump.   Insulin injections continue to be the 
treatment choice for many because of its simplicity and low cost.  Patients receiving this 
type of treatment inject themselves with insulin multiple times a day, with the frequency 
of injections dependent on their lifestyle and the insulin formulation (short, intermediate, 
or long-lasting) used.  Nevertheless, multiple daily injections are inconvenient and 
hypoglycemic occurrences are still common.  An alternative insulin replacement therapy 
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is through the use of external pumps for continuous subcutaneous insulin infusion (CSII).   
It is estimated that 20-25% of type 1 diabetic patients are using insulin pumps [25].  
Evidence suggests that CSII improves blood glucose control and significantly reduces 
hypoglycemic episodes [25, 26].   As current pumps are based on an open-loop system 
where insulin delivery is not automatically adjusted, failure of this treatment can still 
happen due to the need to continually adapt insulin infusion according to blood glucose 
oscillations [25].  Many investigators are currently working towards designing a closed-
loop system, where there is real-time communication between an infusion pump and a 
glucose sensor.  This technology requires a glucose-sensing device capable of modulating 
insulin infusion at all times.  At present, most glucose sensors are lacking in reliability 
and sustained stability, and are still being evaluated in clinical trials.  Intensive insulin 
therapy through injection or pump delivery can delay the onset and reduce the 
progression of chronic diabetes complications, but it also significantly increases the 
occurrences and severity of hypoglycemic episodes [27, 28].  Despite considerable 
improvement in this therapy through the development of novel insulin formulations and 
infusion pumps, tight glycemic control remains difficult to attain. 
Whole pancreas transplantation was the first biological substitute of the β cell 
function.  This treatment approach offers the benefits of the avoidance of insulin 
administration and reduction of hypoglycemic episodes.  A successful pancreas 
transplantation restores glucose homeostasis in a patient and is shown to be more 
effective than intensive insulin treatment [29].  Since the first pancreas transplantation in 
1966 [30], this treatment has progressed significantly, with improved graft and patient 
survival rates [31].   Nevertheless, there are still a high rate of technical failures and risks 
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of post-transplant complications, with thrombosis accounting for more than 70% of all 
the failures that invariably lead to graft loss [32].  Another major downside of this 
procedure is the need for immunosuppression for the rest of the patient’s life; but even 
with immunosuppression, acute rejection of the transplanted pancreas can still occur. 
Alongside pancreas transplantation, islet cell transplantation was progressively 
introduced as a potentially less invasive therapeutic technique.  Islets are usually infused 
into the liver through the portal vein, through the use of ultrasound and radiography.  
Initial trials to implement islet cell transplantation had limited success, with almost all 
failing mainly due to rejection.  However, after the publication of the use of a steroid-free 
protocol in 2000, also known as the Edmonton protocol which established insulin 
independence in 7 diabetic patients [33], islet cell transplantation regained interest among 
many researchers.   Since then, major islet transplant centers have been established and 
refined new procedures, involving the use of low-dose immunosuppressive therapy 
without glucocorticoid drugs, and improved islet preparation have been developed [27, 
34].  Recent data indicate that insulin secretion by the transplant is associated with an 
improvement in the quality of life, with a reduction in hypoglycemic episodes and 
potentially with a reduction in long-term diabetic complications [35-37].  Despite major 
progress in islet cell transplantation, however, its widespread application is limited by the 
need for immunosuppression and shortage of human donors [28, 34].  Even though 
current immunosuppressive therapies are safer than those used in the past, there are still 
increased risks of infection and malignancy due to the toxicity of the drugs.  Furthermore, 
these drugs have diabetogenic properties that may be responsible for the continuous loss 
of β cells [3, 7, 38].  In order to achieve insulin independence, two or more donor 
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pancreata (~10,000 to 14,000 islet equivalents per kilogram of recipient’s body weight) 
are usually needed [28].  Currently, only 0.1% of the type 1 diabetic population could be 
transplanted with the limited supply of donor organs [7].  These difficulties have 
prompted the search for alternative cell sources and the development of encapsulated 
devices to prevent the need for immunosuppressive drug regimes. 
 
2.3  Tissue Engineered Pancreatic Constructs (TEPCs) 
Pancreas and islet transplantation are now the only means of achieving 
physiologic insulin regulation.  There is ongoing research to developing tissue engineered 
pancreatic constructs (TEPCs) to address the problems of immune rejection and donor 
tissue scarcity [39].   TEPCs generally contain living cells within a biocompatible matrix 
which separates the transplanted cells from the host immune system.  The matrix is 
usually surrounded by a semipermeable membrane that allows the passage of nutrients 
and metabolites, including dissolved oxygen, glucose, and insulin, but excludes high 
molecular weight antibodies and cytotoxic cells of the host.  The protection from the host 
immune system also makes possible the use of alternative cell sources, thereby 
alleviating the problem of human donor shortages; alternative cell sources that have been 
investigated include xenogeneic islet cells, β cells genetically engineered to proliferate in 
culture, and non- β cells genetically engineered to secrete insulin in a glucose-responsive 
manner [3].  When designing TEPCs, properties that are desirable include 
biocompatibility of the material, good diffusional properties through the membrane, easy 
implantation and retrievability, and the ability to keep the cells properly nourished and 
thus alive and functional. 
 13
2.3.1  Insulinoma-derived Cell Lines 
A number of different methods have been applied to generate continuous, insulin-
secreting cell lines.  A major advantage of adopting the use of cell lines is that they 
provide an abundant and reproducible source.  Transformed human β cell lines are more 
compatible with the human physiological environment and induce less severe immune 
rejection [40], but the complications in generating allogeneic cell sources have led 
researchers to investigate the use of xenogeneic cell sources instead.  Although 
xenotransplantation is far from becoming a reality due to safety concerns and 
immunological problems, the development of these cell sources are useful for β cell 
research and as a model for the engineering of human islet β cells [40, 41]. 
The laboratory of Shimon Efrat has established successful functional β cell (βTC) 
lines [42-44].  These cells were developed from insulinomas induced in transgenic mice 
expressing the SV40 T-antigen (Tag) under the control of the insulin promoter.  One of 
the earlier variant of these cell lines, βTC3, displays good growth and retention of insulin 
secretion in culture; these cells, however, exhibit glucose-responsiveness within 
subphysiological ranges and uncontrolled proliferation.  To regulate βTC replication, the 
expression of the Tag oncogene was placed under a conditional, bacterial tetracycline 
operon regulatory system [44].  This newer stable cell line, βTC-tet, has shown more 
physiologic responsiveness to glucose and maintains a low hexokinase activity for > 60 
passages [43-45].   When implanted in a syngeneic diabetic mouse model, tetracycline-
induced inhibition of the Tag expression controlled cell proliferation, but cells remained 
viable and capable of glucose sensing and insulin secretion, which led to the correction of 
hyperglycemia [5].  These cells expressed regulated insulin secretion by increasing their 
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insulin release up to 13-fold when a high concentration of glucose was infused in the 
mice.   Encapsulated βTC-tet cells were also successful in  restoring normoglycemia for 8 
weeks in an allogeneic NOD mouse model [46].   
 
2.3.2  Construct Technology 
Microencapsulation devices are extensively used in the development of TEPC due 
to the simplicity of construction, flexibility of modifying the key components, good 
transport properties, and ease of handling and implantation [3, 47].  In such devices, cells 
are typically encapsulated in microspheres (beads) of alginate or agarose gel, and 
sometimes coated with a semipermeable membrane.  Alginate, which exists in varying 
composition and sequence of linear copolymers of 1-4-linked β-D-mannuronic acid (M) 
and α-L-guluronic acid (G), is widely used for reasons including biocompatibility, 
polymerization under physiological conditions, easy gelling kinetics, porosity, and the 
good environment it provides for the encapsulated cells [48-50].  Lim and Sun were the 
first to introduce what is now one of the most common techniques of islet and cell 
encapsulation [51].  Using this method, the cells are suspended in sodium alginate 
solution and the cell suspension is extruded into a calcium chloride solution to form 
beads.  Gelling occurs when the α-L-guluronate alginate residues crosslink with the 
divalent Ca2+ [49].  To add a semipermeable membrane, the beads were incubated in 
poly-L-lysine (PLL) solution, where the incubation time determines the membrane pore 
size.   However, because poly-L-lysine is inflammatory, beads are generally coated with a 
final layer of alginate, forming calcium alginate-PLL-alginate (APA) beads [52].  
Restoration of normoglycemia through implanted islets encapsulated in APA beads has 
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been demonstrated in diabetic murine models and larger animals, including monkeys and 
dogs [51, 53-57].  Although normoglycemia was achieved with these implanted 
constructs, reduced and delayed insulin secretion was still observed in certain cases [58].  
As alginate encapsulation introduces minimal resistance to mass transfer, the observation 
was largely attributed to the occurrence of fibrotic overgrowth.  The intensity of fibrotic 
response can vary significantly, even within the same species, and significantly hinders 
the diffusion of nutrients and metabolites into and out of the constructs.  While 
differences in the tissue donor and recipients strongly influence the extent of the 
overgrowth, incomplete covering of the PLL coating also results in inflammatory 
reactions, usually observed within 1 week post-implantation [6]. 
More recently, many researchers have also investigated the use of non-coated 
barium alginate as an immunoisolation material.  One concern often raised about barium 
alginate beads is the toxic effect it may have on the animals due to the release of barium 
ions [59], although this can be avoided with sufficient cross-linking time and multiple 
washes of the beads before implantation [60].  The cross-linking of alginate with barium 
ions produces a much more mechanically stable matrix than with calcium ions and could 
potentially exclude the entry of antibodies, but this has yet to be investigated [59, 61].  
Implantation of islets encapsulated in barium alginate has shown to be successful in 
restoring normoglycemia in diabetic rodents [62-64]. In fact, when compared to APA 
beads, barium beads were proven to be more biocompatible and capable of prolonging 
the survival of encapsulated adult porcine islets in NOD mice [65].  Even though the 
reasons why barium beads perform so well are not clearly understood, researchers offered 
a few explanations for these observations: the higher biocompatibility due to the absence 
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of PLL, the strong affinity of barium for alginate, and the prevention of communication 
between the encapsulated islets and the splenocytes [3, 62, 65].    
 
2.3.3  In vivo Construct Integration 
Understanding the in vivo environment and how it affects the efficacy of a TEPC 
is crucial in designing the optimal construct for post-implant survival.  Upon 
implantation, the recipient reacts against both the construct material and the islets or cells 
within the constructs [66].  Inflammatory reaction due to a lack of biocompatibility of the 
construct is one of the main reasons for implant failure. This is dependent on the 
composition and purity of the alginate used, and the integrity of the construct, as 
characterized by its stability and physical perfection [7].  However, even if inflammatory 
reaction against the biomaterial is eliminated and the membrane is able to protect the 
transplanted cells from host antibodies, the recipient may still react against proteins 
released or secreted by the cells.  In this context, host antibodies can combine with shed 
donor antigens, forming complexes which bind to the Fc receptor of macrophages. This 
elicits the release of cytokines, nitric oxide, and oxygen radicals, all which are small 
enough to enter the constructs and destroy the cells [63, 67].  
Another challenging issue in vivo is ensuring good mass transfer of nutrients and 
metabolites into and out of the constructs.  Both the construct design and the distance 
between the implantation site and the bloodstream affect the rapidness of response by the 
cells towards changes in blood glucose levels [7, 68].  The transport of oxygen, in 
particular, is especially crucial as its availability strongly influences implant survival and 
function.  As normal pancreatic islets are highly vascularized and thus well oxygenated, 
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encapsulated islets usually suffer from hypoxic stress since revascularization cannot 
occur around the implant and the supply of oxygen is through passive diffusion only [7]. 
Furthermore, any inflammatory reaction towards the implant may result in a further 
decrease in construct oxygenation.  Oxygen limitation compromises insulin secretory 
responses and leads to graft failure [7, 69, 70].  While intact islets have their secretory 
function compromised at oxygen tensions below 60 mmHg, studies have shown that 
βTC3 are more tolerant to hypoxic conditions and therefore may function better than 
islets in implanted constructs [68, 71].  
 Another issue to be considered during the development of a TEPC is the ability to 
monitor implant function in vivo as constructs are usually highly dynamic post-
implantation.  In this regard, Nuclear Magnetic Resonance (NMR) spectroscopy and 
imaging are very useful modalities that can be used to noninvasively track the changes 
occurring to the constructs [52].  Correlations drawn between in vivo measurements and 
end physiological effects, as usually determined through blood glucose measurements, 
can assist in understanding construct function and mechanisms that lead to construct 
failure.   
 
2.4  Perfluorocarbons (PFCs) 
Perfluorocarbons (PFCs) are highly fluorinated compounds wherein all or most of 
the hydrogen atoms in the molecule are replaced with fluorine atoms [72].  These 
compounds are chemically and biologically inert, and are both hydrophobic and 
lipophobic [14, 72]  Due to low intermolecular interactions, PFCs have a capacity for 
dissolving large amounts of respiratory and other nonpolar gases.   The solubility of 
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oxygen in PFC is approximately 10 to 20 times that in water [10].  This unique property 
has been exploited for use by many biotechnologists and clinicians in various biological 
applications.   As PFCs are not miscible with water, they are usually used in the form of 
an emulsion.  They are prepared through homogenization or sonication of the liquid PFC 
and an emulsifier such as Pluronic-68, egg yolk phospholipids, and triglycerides, forming 





       
 
Figure 2.1 PFC emulsion  
PFC emulsions are generally stable, although stability does decrease over time 
through two proposed mechanisms, coalescence and molecular diffusion [73].  After in 
vivo administration, PFCs are not metabolized by the tissues but are cleared by 
circulation and excreted through exhalation [14].   
 
2.4.1  PFCs as Oxygen Carriers 
Due to the high solubility of oxygen in PFCs, these compounds have been utilized 
as oxygen carriers in many biological applications including blood substitutes, organ 
preservation, and tissue engineered devices.  In the development of artificial blood, 






with egg yolk phospholipid and Pluronic-68, Green Cross Corp., Osaka, Japan) was the 
first PFC emulsion commercially made for use as a blood substitute where its safety and 
efficacy was tested in patients with acute anemia.  Although no serious adverse reactions 
were noted in this clinical study, no appreciable beneficial effects of Fluosol-DA were 
seen either [74].  The PFC emulsion did not meet the metabolic oxygen demand as the 
emulsion contained a very low concentration of pure PFC [75].   Since then, many other 
second-generation PFC emulsions with a higher PFC content have been developed 
including Oxyfluor (HemaGen/PFC, St. Louis, MO), Oxycyte (Oxygen Biotherapeutics, 
Inc., Costa Mesa, CA), and Perftoran (Perftorwn, St. Petersburg, Russia) [11, 75].   
Oxygent (60% wt/vol perfluorooctyl bromide with phospholipid, Alliance Corp., San 
Diego, California) in particular, had a high emulsion stability despite its high PFC 
content, and was assessed in a variety of hemodilution studies [76].  In a model of 
anesthesized hemodiluted dogs, administration of Oxygent was effective in maintaining 
tissue oxygenation [77]. Other studies with dogs demonstrated positive findings of 
improved oxygen content and saturation [78] and myocardial contractility properties [79].   
The use of PFCs as blood substitutes has also been tested in humans.  In patients 
undergoing major noncardiac surgery, hemodilution and Oxygent administration was 
shown to reduce the need for blood transfusion [80].  Additionally, when blood 
transfusion is needed, the use of Oxygent was shown to treat such transfusion triggers 
more effectively than autologous blood in orthopedic surgery [81] and prevent 
gastrointestinal tract ischemia in cardiac surgery patients [82].  Despite all the successful 
outcomes, however, the use of Oxygent was eventually suspended due to adverse 
neurological effects.  Even though many PFC emulsions offer attractive characteristics as 
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a blood substitute, there is currently no PFC approved for clinical use in the United States 
due to the secondary effects of the surfactants employed [74].  Further work is being done 
to obtain a safe PFC emulsion; this includes improving the emulsion stability, prolonging 
intravascular persistence of the emulsion, and establishing the appropriate formulations 
with the adequate properties for each application [11]. 
In the area of pancreas preservation, PFC was first used as a component of the 
two-layer method (TLM) developed by Dr. Kuroda in 1988 at Kobe University [83].  In 
this method, the pancreas is suspended between pre- or continuously-oxygenated PFC 
and a standard organ preservation solution, typically University of Wisconsin (UW) 
solution [84].   This cold storage method has been shown to be an effective way of 
preserving the pancreas before islet isolation or transplantation in animal models and also 
clinically.  The TLM reduced ischemic injury and resuscitated the pancreas that 
experienced ischemic injury during preservation, prolonged the preservation period 
before islet isolation, and improved the quality of the pancreas, resulting in a high yield 
of islets during isolation [12, 84-87].  These positive findings were reported for both non-
human and human pancreata [85-89]. One proposed explanation for the observed success 
is the continuous supply of sufficient oxygen from the PFC to the pancreas, thereby 
increasing the synthesis of adenosine triphosphate which maintains cellular integrity and 
controls cell swelling [90].  However, other groups have also observed contrary results 
whereby the TLM does not improve islet isolation or transplantation [18, 19]. For 
example, other studies indicate that there was no significant increase in the yield, purity, 
or function of islets isolated from TLM-preserved pancreas when compared to the UW-
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preserved pancreas.  Furthermore, no significant difference was observed in islet post-
transplant function [18, 19].  
In cell culture and the development of tissue engineered constructs, PFCs are 
being incorporated either in the culture medium or within the tissue constructs to enhance 
oxygenation.  In studies where the PFC phase is convectively transported by medium 
perfusion through the tissue constructs, positive effects of PFC have been observed.  For 
example, in a study by Kinasiewicz et al., medium supplemented with a PFC emulsion, 
Perftoran, was used for the culture of human hepatoma cells seeded on mineral fibers 
coated with collagen type I.  Cells perfused with PFC-containing medium showed 
significant increase in protein synthesis, including albumin, the main protein produced by 
hepatocytes in the liver [15].  Similarly, in the study of Radisic et al., the addition of a 
PFC emulsion, Oxygent, to medium perfusing a parallel plate cardiac bioreactor 
increased the DO throughout the bioreactor and consequently supported a greater density 
of cardiomyocytes.  Further studies with the same system showed improved properties of 
cardiac constructs cultured in PFC-supplemented medium.  Tan et al. also reported on 
increased tissue engineered trachea epithelial oxygenation when the perfused culture 
medium was supplemented with the Oxygent, which subsequently improved epithelial 
metabolism [16].    
On the other hand, in systems where PFC is incorporated to a static culture 
medium, mixed results on the effects of PFC have been obtained.  When PFC-
supplemented medium was used to culture rat islets, Zekorn et al. observed a marked 
increase in insulin secretory function in comparison to medium without PFC 
supplementation [91].   Similarly, Takahashi et al. also reported the use of oxygenated 
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PFC with culture medium to result in better insulin release [92].  While it was suggested 
that the elevated metabolic potency was due to the increased oxygenation, Bergert et al. 
did not observe similar results [20].  The viability and function of PFC-cultured rat islets 
were not significantly better than the control groups without PFC.  In fact, in certain 
cases, there were trends of islet deterioration after PFC treatment [20].  Supporting this 
observation was Terai et al. who demonstrated that the addition of oxygenated PFC to 
UW solution lowered islet quality and was not beneficial in improving the cure rate of 
diabetic rats [93].  In a different system, where a PFC emulsion was encapsulated along 
with human HepG2 hepatomas in calcium alginate hydrogels, cellular growth and 
metabolic activity were shown to increase under both atmospheric and reduced oxygen 
conditions [17, 94].  The contradictory results reported in literature on the effects of PFC 
on organ preservation and on cell or islet viability and function in static systems 
necessitate further investigation.  
 
2.4.2  PFCs as Oxygen Concentration Markers 
PFCs have been increasingly used as physiological markers of tissue oxygenation 
in 19F NMR spectroscopy and imaging [95-99].  The linear relationship between the spin 
lattice relaxation rate (R1 = 1/T1) of the PFC fluorine resonances and oxygen is used as a 
calibration curve (as observed in Figure 2.2 below) to derive oxygen concentration values 
















Figure 2.2 Linear calibration curves of 1/T1 versus oxygen for (a) perfluorotributylamine 
and (b) Fluosol-DA (perfluorodecalin + perfluorotripropylamine).  Figure adapted from 
Parhami et al. [102] and Reid et al.[100] . 
 
 Due to their high oxygen solubility and hydrophobicity, PFCs display excellent 
sensitivity to oxygen and insensitivity to variations in ionic constituents compared to the 
surrounding tissue water [103].  The 19F isotope presents several advantages including a 
100% natural abundance, a relative sensitivity of 83% that of 1H, which is the second 
most sensitive nucleus, and an absence of naturally occurring fluorine in biological 
tissues; this enables signal acquisition of very small amounts of exogenous fluorine [14, 
100].   
Oxygen is crucial in maintaining cellular homeostasis and preserving tissue 
physiological function.   The ability to monitor in vivo oxygen aids in understanding 
mechanisms of tissue function and progression of disease, as well as in clinical prognosis.  
Previous studies have shown the feasibility of using 19F NMR to noninvasively monitor 
oxygen levels in the liver, spleen, lung, heart, and brain through the distribution of PFC 
emulsion in these organs and tissues administered intraveneously or intraperitoneally 
(a) (b) 
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[104-107].  Noth et al. and Zimmermann et al. have also performed quantitative oxygen 
measurements in PFC-loaded alginate beads implanted in the peritoneal cavity, under the 
kidney capsule, and in the muscles of rats to identify the optimal implantation sites for 
cell survival.  They reported low, variable oxygen levels in all the implantation sites [108, 
109].  
Similar monitoring methods have been used in studies of in vivo tumor 
oxygenation.  It is widely recognized that the efficacy of many therapeutic approaches to 
tumor treatment is influenced by oxygen tension [110-113].  Studies have shown that 
chronic hypoxia that develops as large tumors outgrow their blood supply causes tumor 
aggressiveness, metastasis, and resistance to radiotherapy and chemotherapy [110, 114].  
Furthermore, there is a widespread variation in tumor oxygenation where distinct 
heterogeneity exists among tumors independent of type, size, or stage [115, 116].  
Oxygen measurements through 19F NMR have been used to investigate the dynamic 
changes in tumor oxygenation in rats and mice [111, 113, 116, 117].  Also, given the 
resistance of hypoxic tumors to treatment, this method is used to guide oxygen tension 
modulation in tumor tissue through carbogen breathing, a technique used to enhance 
radiosensitization [111, 112, 118].   
In partial liquid ventilation (PLV), gas is delivered into a lung which has been 
filled with PFC to improve gas exchange in patients with acute respiratory distress 
syndrome.  Since PFCs already contain the 19F isotope, they are simultaneously adapted 
as oxygen monitors to quantify oxygen partial pressure in the lungs, to understand the 
mechanisms of action of PLV and to improve treatment efficacy [119].  In studies by 
Laukemper-Ostendorf et al. and Heussel et al., this method was used to qualitatively and 
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quantitatively assess the regional distribution of the oxygen partial pressure in a porcine 
lung during PLV [95, 120].   
PFCs can also be incorporated in tissue engineered constructs to noninvasively 
monitor construct oxygenation. Measuring DO within a construct helps determine the 
physiological status of the cells as there is a high dependence of cell function on oxygen, 
and an almost linear correlation between cell oxygen consumption and the number of 
viable cells [71, 121-123].  For encapsulated cell systems in particular, this method has 
been proven successful in tracking the metabolic state of cells in vitro [9].  The 
experimentally measured DO levels in the constructs were shown to correlate well with 
the encapsulated cell metabolic activity and also to the DO values predicted by a 
mathematical model [9, 124].    
 
2.5  Noninvasive Monitoring of Tissue Engineered Pancreatic Constructs (TEPCs) 
by Nuclear Magnetic Resonance (NMR) Spectroscopy and Imaging 
TEPCs are highly dynamic post-implantation.  The extent of cell growth and 
remodeling, host-construct interaction, diffusion limitation of nutrients and metabolites, 
and the integrity and mechanical stability of the constructs all influence their functional 
outcome [9, 125].  In this context, NMR is a very useful noninvasive modality that can be 
used to probe the structure and function of a TEPC via imaging and spectroscopy, 
respectively [126-128].  The ability to noninvasively monitor the physiological state of a 
construct through NMR enables us to better understand construct function and therefore 
optimize their design.  Dynamic changes occurring to the construct can be evaluated 
directly, therefore reducing the number of animals that needs to be euthanized.  
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Furthermore, it offers an early diagnosis of construct function post-implantation and also 
assists in understanding the underlying mechanisms that lead to implant failure [129].   
  Before implantation, in vitro studies under well controlled conditions are 
essential in understanding cell behavior in an encapsulation environment and in 
developing optimized NMR measurement methods.  Commonly used nuclei to study 
cellular metabolism are 31P and 1H due to their relatively high sensitivity and natural 
abundance.  Metabolites detectable by 31P include nucleotide triphosphates (NTPs), 
whose primary component is attributable to adenosine triphosphate (ATP), inorganic 
phosphate (Pi), phosphocreatine (PCr), and other intermediates in phospholipids 
metabolism [129, 130].  Quantitative analysis of the biochemistry of recombinant, 
insulin-secreting mouse pituitary AtT-20 cells encapsulated as spheroids in alginate was 
initially performed by Constantinidis and Sambanis.  The bioenergetics of cells cultured 
in a fixed bed bioreactor were measured using 31P NMR spectroscopy for a period of 70 
days.  Results showed that the observed changes in high energy phosphates, PCr and 
NTP, were in agreement with changes in the metabolic activity of the cells [131].  Using 
similar methods, Papas et al. studied the effects of repetitive exposure to low or high 
glucose on the bioenergetic status of alginate-encapsulated βTC3 mouse insulinomas 
[132].  It was observed that for βTC3 cells, step changes in extracellular glucose 
concentration did not affect intracellular ATP, and that a correlation between ATP and 
insulin secretion rate existed only under certain culturing conditions [130, 132].  Further 
studies showed that ATP levels were reduced under short- and long-term hypoxia [8, 71].  
Similar correlations between β-NTP and oxygen levels were also observed with βTC-tet 
cells [9].  These studies are useful in identifying key metabolic features of β cells and 
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elucidating mechanisms associated with glucose-stimulated insulin secretion.  
Unfortunately for tissue engineered constructs, 31P sensitivity is still too low for detection 
of metabolites in vivo; therefore, in order to obtain sufficient signal, a high implanted cell 
number is required.  
The 1H nucleus appears to be a good alternative as it has a higher sensitivity when 
compared to 31P.  Nevertheless, a major issue with 1H is the presence of the large water 
signal in biological tissues that masks the detection of intracellular metabolites [133].  To 
circumvent this problem, Long et al. developed solvent-suppression adiabatic pulse 
sequences to minimize the intensity of the water resonance, making it possible to monitor 
1H metabolites, specifically the total choline signal, from alginate-encapsulated βTC3 
cells by NMR.  Initial in vitro studies conducted in a packed-bed bioreactor showed that 
the total choline resonance can be used to track the net cell growth in the system, and is 
sensitive to changes in oxygen concentration [133].  Stabler et al. employed this method 
in a slightly different system where βTC3 cells were encapsulated in agarose disk-shaped 
constructs, and reported a strong linear correlation between total choline and the viable 
cell number and insulin secretion rate [134].  When implanted in the peritoneal cavity of 
mice, total choline measurements acquired noninvasively by localized 1H NMR were 
used to quantify and monitor changes in the number of viable cells over time [125].  1H 
MR imaging techniques have also been developed to visualize both alginate and agarose 
constructs containing βTC3 cells in vitro and in vivo [125, 127, 128, 134].  This method 
was capable of detecting structural changes and host response effects on implanted 
agarose constructs [125].   Barnett et al. tried a different imaging approach by using PFCs 
as 19F MR contrast agents.  19F images of PFC-containing encapsulated islets implanted 
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in the peritoneal cavity were overlaid over anatomic 1H MR images.  Using this 
approach, the constructs were easily distinguishable from the surrounding tissues [135].   
With the development of higher magnetic field strengths and better coil designs, in vivo 
NMR measurement sensitivity has been significantly improved, and spectroscopy and 
imaging methods are becoming more feasible [136]. 
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CHAPTER 3 
LIMITED BENEFICIAL EFFECTS OF PERFLUOROCARBON 
EMULSIONS ON ENCAPSULATED CELLS IN CULTURE: 
EXPERIMENTAL AND MODELING STUDIES* 
 
3.1  Abstract 
Due to the high solubility of oxygen in perfluorocarbons (PFCs), these 
compounds have been explored for improved cell and tissue oxygenation.  The goal of 
this study is to investigate the effects of a PFC emulsion on cellular growth and function 
in a tissue engineered construct. A perfluorotributylamine (PFTBA) emulsion was co-
encapsulated at 10 vol% with mouse βTC-tet insulinoma cells in calcium alginate beads 
and cultured under normoxic and severely hypoxic conditions.   The number of 
metabolically active cells and the induced insulin secretion rate were measured over time 
for up to 16 days.  Results showed no significant effect of PFTBA relative to the PFTBA-
free control.  The alginate-PFC-cell system was also modeled mathematically, and 
simulations tracked the number of viable cells over time under the same conditions used 
experimentally.  Simulations revealed only a small, likely experimentally undetectable 
difference in cell density between the PFC-containing and PFC-free control beads.  It is 
concluded that PFTBA up to 10 vol% has no significant effect on the growth and 
function of encapsulated βTC-tet cells under normoxic and hypoxic conditions.  
 
* Modification of a paper published in the Journal of Biotechnology, 2010 Oct 15; 150(2):232-9 
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3.2  Introduction 
A major challenge in developing and implementing tissue engineered substitutes 
is ensuring sufficient oxygenation of cells within constructs, as oxygen is a significant 
parameter affecting cell viability and function [8, 9, 71].  This is especially true for 
substitutes which rely on diffusion for the transport of dissolved oxygen.   Therefore, a 
means of enhancing oxygen delivery by increasing the solubility and/or diffusivity of 
dissolved oxygen within a construct might prove beneficial and desirable.   
The high solubility of oxygen in perfluorocarbons (PFCs) has led investigators to 
explore their use in the form of a non-aqueous phase or an emulsion, as a blood 
substitute, in organ preservation, and in tissue engineered devices.  It is reasonable to 
expect a positive effect in systems where the PFC phase is convectively transported 
between an oxygenator and a culture or tissue where oxygen is delivered and used.  This 
has been confirmed experimentally, as in the study of Radisic et al. who demonstrated 
that adding the PFC emulsion, Oxygent, to medium perfusing a parallel plate cardiac 
bioreactor increased the dissolved oxygen concentration (DO) throughout the bioreactor 
and consequently supported a greater density of cardiomyocytes [137].  In their system, 
the DO in the medium entering the bioreactor was kept constant at 160 Torr using a gas 
exchanger, thereby replenishing the PFC emulsion with oxygen after each bioreactor 
pass.  Further studies with the same system showed improved properties of cardiac 
constructs cultured in PFC-supplemented medium [138]. 
In systems where PFCs are not convectively transported, enhanced oxygenation 
can be achieved by the delivery of oxygen from the PFC to an aqueous phase in contact, 
and/or by the increased effective diffusivity realized when PFCs are dispersed as an 
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emulsion in an aqueous phase.  An example of the former is the two-layer method (TLM) 
of pancreas preservation, in which the organ is suspended between University of 
Wisconsin (UW) solution and oxygenated PFC.  The PFC layer serves as an oxygen 
reservoir, while the UW solution provides other nutrients, including adenosine to 
promote ATP synthesis in the tissue [84].  With non-human pancreata, there exist reports 
of significantly improved islet yield and in vitro function when islets were isolated from 
organs preserved in the TLM relative to organs preserved in UW solution alone [85, 89].  
Improved islet yields for pancreata preserved by the TLM versus the UW solution alone 
have also been reported for human tissues [86-88].   Other groups have observed contrary 
results, however, in which the TLM did not improve islet isolation or transplantation 
outcomes.  For example, Caballero-Corbalan et al. compared the outcome of 200 human 
islet isolations performed after storage in either the UW solution only or by the TLM 
over short (<6 hours) or prolonged (up to 18 hours) cold ischemic time.  They observed 
no significant improvement in the islet yield, purity, or function with the TLM [139].  
Similarly, Kin et al. reported no beneficial effects of the TLM on human islet isolation 
and transplantation [18].  Papas et al. offered a mechanistic explanation of these 
outcomes, in that PFCs do indeed improve oxygenation but only in a thin peripheral layer 
of tissue, while oxygen is not delivered to inner tissue domains [140].  For this, 
convective oxygen transport through the native organ vasculature may be necessary. 
PFC addition to culture media has also produced mixed results.  With rat islets in 
culture, Zekorn et al. observed a marked improvement in islet insulin secretory function 
when the culture medium was supplemented with PFCs [91].  On the other hand, Bergert 
et al. [20] did not observe similar results.  In the latter study, the effects of PFCs on islet 
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viability and function were characterized by measuring cell death, apoptosis, mRNA 
levels of insulin, insulin content, and stimulated insulin secretion.  These extensive 
measurements indicated that the incorporation of PFC failed to provide any advantage 
over conventional protocols for islet culturing [20].   
In tissue engineering, there is a gaining interest to incorporate PFCs in hydrogels 
to improve the oxygenation of encapsulated cells.  Khattak et al. reported that 
encapsulating a PFC emulsion along with human HepG2 hepatomas in calcium alginate 
hydrogels increased cellular growth and metabolic activity over a 10-day period [17, 94].  
With islets, mathematical simulations indicated that cell oxygenation was improved when 
a PFC emulsion was incorporated at a 70% PFC concentration in the encapsulating 
material, or when islets were dispersed into smaller aggregates, in both spherical 
microcapsules and planar slabs [141].  It is generally accepted that in these systems PFCs 
increase oxygenation by enhancing dissolved oxygen effective diffusivity through the 
matrix, not by serving as an oxygen reservoir, as the PFCs have only limited capacity to 
supply oxygen and they do not become reoxygenated.  However, it remains unclear 
whether the increase in effective diffusivity is sufficient to produce consistent, 
statistically significant, and experimentally measurable positive effects, especially in 
applications with encapsulated insulin-secreting cells, which constitute a commonly used 
architecture for a pancreatic tissue substitute.  Furthermore, in the design of such systems, 
it would be important for the PFC to be incorporated at a concentration that does not 
compromise the mechanical integrity and immunoprotective properties of the 
encapsulating matrix. 
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 In this study, we addressed this question by investigating experimentally the 
effect of a PFC emulsion, perfluorotributylamine (PFTBA), on the viability, metabolic 
activity, and insulin secretory function of mouse βTC-tet insulinoma cells encapsulated in 
calcium alginate beads and cultured under normoxic and hypoxic conditions.  We limited 
the PFTBA concentration to 10 vol% to ensure that the bead properties would not be 
compromised, as the alginate/PFC beads were unstable when prepared with higher PFC 
concentrations.  Furthermore, we constructed a mathematical model of the alginate-PFC-
cell system and compared simulations with the experimental results.  The implications of 
our findings in the development of pancreatic substitutes based on encapsulated cells are 
discussed.   
 
3.3  Materials and Methods 
3.3.1  Cell culture and Cell Encapsulation 
Murine insulinoma βTC-tet cells [142] were obtained from the laboratory of 
Shimon Efrat, Albert Einstein College of Medicine, Bronx, NY.  Cells were cultured as 
monolayers in T-175 flasks, in a 37oC, 5% CO2 humidified incubator. Culture medium 
consisted of Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma Chemical Co., St. 
Louis MO) with 25 mM glucose, supplemented with 10% fetal bovine serum, 1% 
penicillin-streptomycin, and L-glutamine to a final concentration of 6 mM, and it was 
changed every 2-3 days.  Cell monolayers that reached 80% to 90% confluency were split 
by treatment with 0.25% trypsin-EDTA (Sigma); passage number increased by one at 
each splitting.  Cells of passage number 36-48 were used in this study.   
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For encapsulation, cells were harvested by trypsin-EDTA and encapsulated at a 
density of 3.5×107 cells/ml in 2% w/v low viscosity, high mannuronic content alginate 
(product LVM, NovaMatrix, Drammen, Norway) containing the appropriate 
concentration of PFTBA emulsion (0 or 10 vol%).  Using an electrostatic droplet 
generator (Nisco Engineering Inc., Zurich, Switzerland), cells were encapsulated 
according to the procedure of Stabler et al. [143].  Certain alginate bead preparations 
were coated with poly-L-lysine (PLL) (MW = 19,200; Sigma, St. Louis, MO) and a final 
alginate layer to form alginate/PLL/alginate (APA) beads.  The coating protocol was as 
described by Papas et al. [144], which was based on a protocol by Lim and Sun [145].  
Studies were performed with two bead sizes, 500 ± 150 µm and 1000 ± 200 µm in 
diameter.   
The PFTBA emulsion was prepared following a protocol adapted from Joseph et 
al. [146].  An amount of 600 µl of Tyrode’s salt solution (Sigma) was added to 95 mg of 
egg yolk lecithin (~99% purity, Sigma) and sonicated twice for 15 seconds at 300 W, 
with a one minute interval between each sonication.  An amount of 400 µl of PFTBA 
(Sigma) was then added to the mixture and sonicated the same way for ten times  The 
emulsion was filtered through a 0.8 µm membrane filter (Millipore, Billerica MA) and 
added to alginate at a 1:10 ratio.  For one of the control groups, 1000 µl of Tyrode’s salt 
solution was added to 95 mg of egg yolk lecithin and sonicated twelve times.  This 





3.3.2  Culturing of Encapsulated Cells 
Alginate-encapsulated βTC-tet cells were cultured in a 37°C, 5% CO2 incubator 
for 1 day before experimentation to allow for recovery from the encapsulation procedure.  
The coating procedure was carried out a day after encapsulation.  For normoxic 
experiments, encapsulated cells were placed into T-75 flasks and cultured on a rocking 
platform in a 37°C, 5% CO2 incubator for 16 days.  Number of metabolically active cells 
and insulin secretory function were assessed on Days 1, 2, 4, 8, 12, and 16.  For hypoxic 
experiments, T-flasks or multiwell plates were placed in a Plexiglas chamber with inlet 
and outlet ports, which was placed on a rocking platform in a 37oC incubator.  A gas 
mixture of 5% CO2 balanced with N2 was continuously supplied through the chamber, 
lowering the oxygen to a severely hypoxic level of approximately 2% air saturation, as 
measured by an oxygen polarographic sensor (Ingold Messtechnik, Urdorf, Switzerland).  
For experiments under long-term hypoxia, encapsulated cells in T-75 flasks were cultured 
in the chamber for 13 days.   Number of metabolically active cells and cell viability were 
assessed on Days 1, 4, 7, 10, and 13.  For short-term hypoxic experiments, encapsulated 
cells were transferred to a 6-well plate and cultured in the chamber for 3 hours. Insulin 
secretion tests were then carried out, also in the chamber.  In all studies, cells were fed by 
completely replacing the medium with fresh every 2-3 days. 
To measure the rates of glucose consumption of encapsulated cells under 
normoxia, 0.5 ml of beads were cultured in 2.5 ml of fully supplemented medium in T-
12.5 flasks for 7 days.  Medium samples of 1.0 ml volume were collected daily and 
replaced with fresh medium.  Rates of glucose consumption were evaluated by measuring 
the concentrations in samples. 
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3.3.3  Insulin Secretion Measurements 
A bead volume of 0.1 ml was removed from the main culture and loaded in a well 
of a 6-well plate, which was placed on a rocking platform in a 37°C, 5% CO2 incubator, 
or, for hypoxia studies, in the chamber.  The beads were exposed to 5.0 ml of basal 
medium (glucose-free, non-supplemented DMEM) for 60 min, then switched to 3.2 ml of 
stimulating medium (16 mM glucose, fully supplemented DMEM) for 30 min.  Medium 
samples withdrawn at the start and end of each stimulation period were stored at -80oC 
for later assay of insulin by radioimmunoassay.  The beads used in these insulin secretion 
experiments were not returned to the main culture.  The 30 min secretion period was 
sufficient to capture the stimulated secretory response [147].  Secretion rates were 
calculated in pmol insulin per hour per 108 cells.    
 
3.3.4  Assays 
Numbers of metabolically active encapsulated cells were measured using the 
metabolic indicator alamarBlueTM (Invitrogen Corp, Carlsbad, CA).  A bead volume of 
0.1 ml was placed in a well of a 12-well plate and mixed with 1.0 ml of medium and 0.1 
ml of alamarBlueTM reagent.  Plates were positioned on a rocking platform in a 37°C, 5% 
CO2 incubator.  After 1.5 hours (3 hours for hypoxia experiments), 0.1 ml medium 
sample was withdrawn from each well, and its absorbance measured using a Spectra Max 
Gemini Plate Reader (Molecular Devices, Sunnyvale, CA) with an excitation wavelength 
of 544 nm and an emission wavelength of 590 nm.  Relative intensity units (RIUs) were 
normalized to the RIUs of the Day 1 samples measured under the same conditions.  Cell 
viability was determined using Trypan Blue assay (Sigma), where  0.1 ml of alginate 
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beads were dissolved in 0.2 ml of 2% sodium citrate solution (Sigma).  A volume of 0.1 
ml of the resulting suspension was added to 0.2 ml of Trypan Blue reagent and loaded on 
a hemocytometer for cell counting. 
Insulin concentration in collected samples was assayed by rat insulin 
radioimmunoassay (Linco Research, St Charles, MI), using a CobraTM II Series Auto-
Gamma Counter (Packard Instruments).  Glucose concentrations were  determined by the 
Glucose Trinder Assay (Diagnostic Inc., Oxford, CT), with absorbance measured at 505 
nm wavelength using a SpectraMax Plus Plate Reader (Molecular Devices, Sunnyvale, 
CA). 
 
3.3.5  Statistical Analysis 
 Statistical significance of differences between experimental groups and days were 
evaluated using General Linear Model, ANOVA.  Statistical significance was defined as 
p<0.05. 
 
3.3.6  Mathematical Simulations 
 The mathematical model used to simulate the system of encapsulated cells with a 
perfluorocarbon emulsion was an extension of the previously published model of Gross et 
al [148].  The assumptions incorporated in the model are listed below.  
1. Dissolved oxygen is the only nutrient that limits cell proliferation (i.e., all other 
essential nutrients are in excess throughout the construct). 
2. Spatial constraint is the only other factor besides DO that limits the rate and 
extent of cell proliferation within the construct. 
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3. As cells cannot adhere to the alginate matrix, cells do not migrate within the 
matrix; hence any remodeling in cell distribution is due entirely to cellular growth 
and death at each locale. 
4. The PFC emulsion is homogeneously distributed throughout the contiguous 
alginate matrix. 
5. Equilibration of dissolved oxygen between the aqueous and PFC phases at each 
locale is instantaneous.   
6. The values of the model parameters, including the effective diffusivity of oxygen 
through the encapsulated system, remain constant over the time period of the 
simulations. 
7. The concentration gradient within the aqueous phase is the only driving force for 
oxygen diffusion. 
8. There is no external boundary layer effect when modeling the beads placed in 
well mixed medium, as in this study.   
Figure 3.1 is a schematic of the configuration that is considered.  Volume elements along 
a bead radius each consist of an aqueous and a PFC phase, with cells present in the 
aqueous phase only and dissolved oxygen in both phases.  Diffusion of oxygen occurs 
between compartments, and the aqueous and PFC phases in each compartment are always 









Figure 3.1   Configuration considered to solve for the DO profile.  In solving for the total 
DO (CT, amount of oxygen in aqueous plus PFC phases divided by the compartment 
volume) at compartment ‘0’, diffusional transport occurs by the DO differences in the 
aqueous phase (Caq) between compartment ‘0’ and the neighboring compartments (‘-1’ & 
‘+1’).  Additionally, the DO in the PFC and aqueous phases, CP and Caq, respectively, are 
always in equilibrium based on the partition coefficient.  Parameter S(r) is the oxygen 
consumption rate by the cells per unit volume of aqueous phase, as described in Equation 
(3). 
 
The model equations describing oxygen diffusion for spherical geometry are as follows 
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where, t is time and r is radial position in the construct; CT(r,t), Caq(r,t), and Cp(r,t) are 
the DO in the total volume (VT), the volume of the aqueous phase (Vaq), and the volume 
of the PFC phase (Vp), respectively, as functions of radial position and time;  Deff is the 
effective oxygen diffusivity through the alginate/PFC matrix; VT, Vaq, and Vp are the total, 
aqueous, and PFC volumes; S(r,t) is the rate of oxygen consumption per unit volume of 
aqueous phase as a function of radial position and time, which is based on a Monod 
model with kinetic parameters νmax (maximum oxygen consumption rate) and Km (Monod 
model parameter); and  X(r,t) is the cell density as a function of radial position and time.   
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The effective diffusivity was calculated using the equation given by Radisic et al. 































p=           (6) 
In the above equations, Daq and Dp are the diffusivities of oxygen through the aqueous 
calcium alginate phase and the PFC phase, respectively; K is the partition coefficient of 
oxygen in PFC vs. the aqueous phase; and φ  is the volume fraction of the PFC emulsion 
(Vp/VT). 
 The equations used for determining the growth and death of cells radially through 
the alginate matrix over time are the same as reported in Gross et al [148] and are listed 
below. 
( )dgaqaq μμ(r,t) Xdt
(r,t)dX
−=        (7) 
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(Monod’s model for the specific growth rate μg with kinetic parameters μg,max and Kg, 








−−= minmaxmax          (9) 
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(modified Monod’s model for the specific death rate μd  maximizing the cell death rate at 
Caq=0 and minimizing it at Caq>>Kd) 
In the above equations, μg and μd are the specific cell growth and death rates, 
respectively; μg,max and μd,max are the maximum specific growth and death rates, 
respectively; μd,min is the minimum death rate, which prevails under an abundance of 
oxygen; Kg and Kd are Monod model parameters; and Xmax in the maximum cell density 
that can be accommodated in the construct.  The ratio X/Xmax is thus the fractional 
maximum occupancy at a particular locale in the construct. 
 
Initial and boundary conditions  
Equations (1)-(8) were solved with the following initial and boundary conditions. 
oaq C)t,r(C == 0               (10) 
(the initial concentration of oxygen throughout the spherical construct is constant and 
known) 
oaq X)t,r(X == 0              (11) 







Caq              (12) 
(symmetry condition for oxygen concentration at the center of the sphere) 
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To simulate encapsulated cells in an infinite volume of medium, Equation 13 was used: 
baq C)t,Rr(C ==                     (13) 
(DO at the surface of the bead is equal to the DO in the surrounding medium, Cb, which 
is known and assumed constant).  This approximates beads cultured in T-flasks, in a large 
volume of medium on a rocking platform.   
The appropriate initial and boundary conditions, and baseline parameter values 
listed in Table 3.1 were used.   
Table 3.1    Baseline parameter values used in simulating the temporal profiles of cell 
density and DO in the system of βTC-tet cells encapsulated in spherical calcium alginate 
beads with and without a perfluorocarbon emulsion. 
Parameter Value Reference
Diffusivity of oxygen in cell‐containing alginate D aq 1.4 cm
2/day [152]
Diffusivity of oxygen in PFTBA D p 4.85 cm
2/day [199]
Partition coefficient of oxygen between PFTBA and water  K 16 [153]
Maximum oxygen consumption v max 2.88 mmole/(day x 10
9 cells) [152]
Monod parameter ‐ oxygen K m 0.01 mM [152]
Maximum specific growth rate µ g,max 0.04 day
‐1
Sensitivity analysis
Maximum specific death rate µ d,max 1.4 day
‐1
[200]
Minimum specific death rate µ d,min 0.00273 day
‐1
[152]
Monod parameter ‐ growth K g 0.01 mM [152]
Monod parameter ‐ death K d 0.001 mM [152]
Maximum cell density X max 9 x 10
8 cells/ml  Calculated based on a 
8.1 x 108 cells/ml (With PFC) 10 µm diameter cell  
The ratio of the diffusion coefficient of oxygen in the PFC vs. the aqueous phase 
is 3.46.  With this value and the partition coefficient being equal to 16, the effective 
diffusivity in the composite alginate/10% PFC material was calculated from equations 
(4), (5) and (6) to be 1.8 cm2/day, compared to 1.4 cm2/day for the alginate-only material. 
Model equations were solved using finite differences.  From Caq(r,t), the average aqueous 
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3.4  Results and Discussion 
3.4.1  PFTBA Effects on Encapsulated βTC-tet Cells under Normoxic Conditions 
 Cell metabolic activity in APA beads with no PFTBA (Control 1), 10 vol% 
lecithin solution (Control 2), and 10 vol% PFTBA emulsion (Experimental) was assessed 
over a period of 16 days.  The second control group was included to ensure that lecithin, 
the emulsifier used to make the PFTBA emulsion, did not have an effect on cells by 
itself, and that any changes observed in the PFC group were solely due to the presence of 
PFTBA.  The droplet size of the PFTBA emulsion in the alginate beads was measured 
microscopically and remained at 1-2 µm throughout the experimental period, indicating 
that the emulsion was stable.   The integrity of APA beads was also maintained 
throughout this period as the PLL layer reduced the diffusion of calcium ions out of the 
alginate matrix and has an overall stabilizing effect on the beads [50, 149].  All data were 
normalized to the measurement on Day 1, which was set equal to 1.  Results with 1000 
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Figure 3.2  Metabolic activity of encapsulated βTC-tet cells under normoxic conditions.   
The number of metabolically active cells was measured as a function of time by 
alamarBlueTM and normalized to Day 1.  Measurements were performed with calcium 
alginate/ poly-L-lysine/ alginate (APA) beads of 1000 μm average diameter with no 
PFTBA, APA beads with 10 vol% lecithin, and APA beads with 10 vol% PFTBA (n = 3 
each).  The initial density of the encapsulated cells was 3.5×107 cells/ml.   * p<0.05 when 
compared to Day 1. 
 
There was a gradual increase in the number of metabolically active cells over time for all 
groups.  This trend is compatible with earlier findings with βTC insulinomas 
encapsulated in high mannuronic alginate beads [143].  At any particular time point, there 
were no statistical differences in metabolic activity among the different groups of beads. 
Data on the insulin secretion rates (ISR) measured under 16 mM glucose 
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Figure 3.3 Stimulated insulin secretion rate (ISR) of βTC-tet cells under normoxic 
conditions.  ISR was measured over 30 min of stimulation by 16 mM glucose, normalized 
to the initial number of encapsulated βTC-tet cells, and expressed on a per unit time 
basis.  Measurements were carried out with 1000 μm average diameter APA beads with 
no PFTBA, APA beads with 10 vol% lecithin, and APA beads with 10 vol% PFTBA (n = 
3 each).  Each glucose stimulation episode followed 1 hour of exposure to basal, 0 mM 
glucose, medium.  * p<0.05 when compared to Day 1. 
 
There was a general increase in ISR with time up to Day 16 for all groups.  As 
with the alamarBlueTM measurements, there were no statistical differences in ISR among 
the different bead groups at any time point.  However, the temporal increase in insulin 
secretion was higher than the increase in metabolic activity shown in Figure 3.2, 
suggesting an increase in the insulin secretion rate per cell over time.  Although the 
precise reason for this is unclear, it is possible that it was caused by an increasing 
hypoxic environment within the bead due to cell growth, which resulted in higher lactate 
production and locally more acidic conditions over time; an acidic pH has been shown to 
cause elevated insulin release from βTC3 cells, an earlier variant of the βTC-tet 
insulinoma line [150].   
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It should be noted that similar results were obtained with βTC-tet cells 
encapsulated in calcium alginate beads without PLL coating of both 500 and 1000 μm 
beads (n = 4, results shown in Figure A2.a in Appendix II).   In these experiments, too, 
there were no differences in metabolic activity or insulin secretion rates between PFTBA-
containing beads and PFTBA-free controls at all time points (n = 4, results shown in 
Figure A2.b in Appendix II).  However, the integrity of these beads started to become 
compromised towards the end of the 16-day experiment due to the absence of the 
stabilizing PLL layer. 
The effects of PFTBA on the glucose consumption rate (GCR) were also studied 
with βTC-tet cells encapsulated in 1000 μm average diameter calcium alginate beads 
with no PFTBA (control 1) and 10 vol% PFTBA emulsion.  The GCR in both bead 
groups increased by approximately 60% over seven days of culture due to cell growth.  
However, the presence of PFTBA had no significant effect on the GCR of the cells over 
that time period (n = 4, results shown in Figure A2.c in Appendix II). 
 
3.4.2  PFTBA Effects on Encapsulated βTC-tet Cells under Hypoxic Conditions 
Figure 3.4(a) shows the temporal profile of the cell metabolic activity, measured 
by alamarBlueTM and normalized to Day 1, for βTC-tet cells in 500 μm alginate-only 
beads with no PFTBA (Control) and 10 vol% PFTBA emulsion, under severely hypoxic 
conditions (~2% air saturation, or 0.004 mM).  The percent viability of the cells in the 
beads was also measured by Trypan Blue and is reported in Figure 3.4(b).  A smaller 
bead size was chosen for this hypoxic study to ensure that the only oxygen-limiting factor 





























Figure 3.4 Metabolic activity and % viability of encapsulated βTC-tet cells under 
severely hypoxic conditions (2% air saturation, or 0.004 mM).   (a) The number of 
metabolically active cells and (b) % viability were measured by alamarBlueTM and 
Trypan Blue respectively, as a function of time and normalized to Day 1.  Measurements 
were performed with calcium alginate beads of 500 μm average diameter with no PFTBA 
and 10 vol% PFTBA (n = 5 each).  * p<0.05 when compared to Day 1. 
 
Results showed that both the metabolic activity and the cell viability for the two 
groups of beads declined significantly from Day 1 to Day 4, to a lesser extent from Day 4 
to Day 7, and stayed at a very low level until the end of the experiment on Day 13.  As 
with the normoxic experiment, there were no statistical differences in cell metabolic 
activity and viability between the two bead groups at any time point.  Due to the 
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 Experiments were also carried out under short-term hypoxia to investigate 
whether the PFTBA phase had a significant effect on the encapsulated cells under these 
conditions.  For this, cells in 500 μm alginate-only beads with no PFTBA (control) and 
10 vol% PFTBA emulsion were cultured under hypoxia for 3 hours, then subjected to an 
insulin secretion test, also under hypoxia.  Results on ISR measured over 30 min under 








Figure 3.5 Stimulated insulin secretion rate (ISR) of βTC-tet cells under severely 
hypoxic conditions.  The encapsulated cells were cultured for 3 hours under hypoxic 
conditions, then subjected to a secretion test.  The secretion episode consisted of cells 
exposed for 1 hour to basal, 0 mM glucose medium, followed by a 30 min of stimulation 
in 16 mM glucose medium, all under hypoxia.  The ISR over the stimulation period was 
measured and is reported in the figure (n = 5 each).  The ISR under normoxic conditions 
is included for reference (n = 1 each).  Beads were of 500 μm average diameter.   
 
 
The insulin secretory function of the encapsulated cells was compromised under the 
hypoxic conditions implemented; however, the presence of 10% PFTBA did not have an 
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3.4.3  Simulations under Normoxic Conditions 
The model equations were solved to calculate the concentration of oxygen, Caq 
and cell density in the aqueous phase, Xaq as functions of radial position and time for 
beads of 1000 μm in diameter.  Figures 3.6(a) and (b) show the time profiles of the cell 
density, normalized to Day 1, along with experimental data on cell metabolic activity 
















Figure 3.6 Simulated temporal profiles under normoxic conditions (0.2 mM).   The 
model equations were solved for 1000 µm average diameter beads to calculate the cell 
density (a) and the average intrabead DO (AIDO) (b) in the aqueous phase in beads 
containing no PFC and 10% PFC.  Simulated values are compared to the experimental 
data shown in Figure 3.2 obtained from APA beads under similar conditions.  In (a), the 
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The cell growth predicted by the model is in good agreement with the 
experimental results for the APA beads.  Due to the increased effective diffusivity in the 
composite alginate/PFC phase, the AIDO for the PFC-containing beads started at a higher 
value of 0.186 mM, when compared to 0.182 mM for the control beads (Figure 3.6(b)).  
As the cell density, and hence the oxygen consumption, increased within the beads over 
time, the AIDO declined accordingly.  The decrease in AIDO, however, was smaller in 
the PFC-containing beads relative to the control, and on Day 16 the AIDO were 
calculated to be 0.172 and 0.165 mM for the PFC and control beads, respectively.  
Although the presence of PFC improved the dissolved oxygen effective diffusivity and 
the AIDO in the beads, this supported only a slightly higher cell density relative to the 
PFC-free control.  The maximum difference in simulated cell densities was on Day 16, 
where the control and PFC beads had cell densities of 7.75 and 7.79×107 cells/ml, 
respectively.  This difference is small, making it essentially impossible to detect 
experimentally.   
These findings are different from those reported by Khattak et al. [17] and by 
Chin et al. [94], who observed a statistical increase in the density of HepG2 cells 
encapsulated in calcium alginate containing 10% perfluorooctylbromide (PFOB) relative 
to PFC-free controls.  The reason for this difference is not clear.  The oxygen solubility is 
higher in PFOB relative to PFTBA, with the partition coefficients being 17.7 and 16 
respectively.  This, however, results only in a minimal difference in the effective 
diffusivities calculated by equations (4), (5) and (6), with values being the same within 
two significant figures, so the difference in solubility cannot explain the difference in 
results.  A second possibility is the lower maximum oxygen consumption rate (vmax) of 
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βTC-tet relative to HepG2 cells.  Indeed, reported vmax values for HepG2 cells of 5.44 
[94] and 17 mmol/(109 cells·day) [151] are significantly higher than the 2.88 mmol/(109 
cells·day) reported for βTC3 cells [152], resulting in a higher oxygen demand in the 
alginate matrix.  A third possibility would be the higher growth rate of HepG2 cells both 
as monolayers and in beads, which may also result in a higher oxygen demand in the 
beads over time. 
We therefore investigated the sensitivity of the model solutions to the values of 
vmax and µg,max.  Simulations were run with vmax equal to the value used in this study and 
the two values for HepG2 cells reported above; for µg,max, model solutions were 
calculated with the value used in this study and with a higher value of 0.35 day-1, which 
corresponds to a much faster growing cell type with a doubling time of 2 days [148].  The 
rest of the model parameters were kept as in Table 3.1, including the maximum cell 
density of 9×108 cells/ml in beads.  Results are plotted as factor increase in cell density in 
the PFC-containing beads relative to PFC-free control vs. time and are shown in Figure 




















Figure 3.7  Simulated factor increase in cell density vs. time resulting from the 
incorporation of 10% PFC relative to PFC-free control for 3 different oxygen 
consumption rates, vmax (mmol/(109 cells·day)) and 2 different growth rates, µg,max (day-1).  
Remaining model parameters are the same as those reported in Table 3.1.  
 
As expected, cells with a higher µg,max arrive at their steady state cell density 
sooner, and the PFC effect increases with vmax, or as the oxygen demand within the 
alginate matrix increases.  However, the cell density supported by the presence of PFC is 
predicted to be no more than 11% higher than the control, which may be detectable 
experimentally but does not improve the performance of the system in a substantive way.  
 
3.4.4  Simulations under Hypoxic Conditions 
Simulations on the effect of PFC on encapsulated cells under severely hypoxic 
conditions were also carried out for 500 µm beads.  Figure 3.8(a) shows the time profiles 
of the cell density, normalized to Day 1, along with experimental data from Figure 3.4A 
on cell metabolic activity, under 0.004 mM external DO over 13 days in culture.  Figure 





































































and 10% PFC; the inset in this figure shows the same AIDO profiles under higher 




























Figure 3.8  Simulated temporal profiles under hypoxic conditions (0.004 mM).  Model 
solutions for cell density (a) and average intrabead DO (AIDO) (b) in the aqueous phase 
of 500 µm average diameter beads containing no PFC and 10% PFC.  Simulated values 
are compared to the experimental data obtained from calcium alginate beads under 
similar conditions and reported in Figure 4.   In (a), the scale of the graph makes the 
simulations for the 10% PFC and control beads essentially coincide.  The inset in (b) 
shows the change in AIDO for the initial 2 min.   
 
Model-predicted cell densities for both groups of beads decreased drastically 
within the first 4 days, which was also reflected in the increase AIDO towards the 
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agreement with the experimental results.  However, the model appears to underestimate 
the number of metabolically active cells on Days 7, 10, and 13.  This could be due to the 
beads being temporarily removed from their hypoxic environment at every experimental 
time point from Day 4 onwards, which is not accounted for in the model.   
As with the normoxia simulations, the AIDO in the PFC-containing beads started 
at a higher value of 0.033 mM, when compared to 0.031 mM in the control beads (Figure 
3.8(b)).  This difference was not significant enough to change the rate of cell death under 
hypoxia.  At Day 4, simulations showed only a slightly higher cell density of 5.96×106 
cells/ml in the PFC-containing relative to 5.77×106 cells/ml for the control.   At steady 
state, the presence of PFC only sustained a cell density that is 3.7% higher than the 
control beads under these conditions.   The model also shows that the capacity of PFC to 
provide oxygen to the aqueous phase is only minimal, as observed by the decrease in the 
AIDO within the first 2 minutes after exposure to the hypoxia (Figure 3.8(b) inset).  This 
lack of significant difference in the calculated cell density between the two groups of 
beads demonstrates the limited capacity of PFC to provide long-term oxygen support to 
the construct under the conditions examined.  
PFCs are effective as oxygen carriers when convectively transported from a 
domain of high oxygen, where they become oxygenated, to a domain of low oxygen, 
where they deliver the oxygen they contain.  This is supported by the fact that oxygen is 
not chemically bound to the PFC carrier and that the thermodynamics of oxygen 
absorption by PFC follow a linear Henry law profile rather than a sigmoidal profile, as is 
the case for hemoglobin [153]. Our study shows, however, that in a stationary system, 
such as an encapsulated cell construct, the increase in construct oxygenation due to the 
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addition of 10% PFC had a minimal effect on the viable cell number and function when 
cultured in a high or low oxygen environment.  A system in which the incorporation of 
PFC would potentially have an added benefit in maintaining viable cells is when the 
culture is surrounded with a large volume of PFC.  This is, however, not feasible with 
encapsulated cells where the PFC emulsion is dispersed, as having a high concentration 
of PFC emulsion will compromise the integrity of the beads and possibly result in 
cytotoxic effects from the emulsifier.  Furthermore, the cell density that can be 




In summary, the addition of PFTBA emulsion of 10 vol% to encapsulated systems 
of βTC-tet cells in calcium alginate beads did not have a statistically significant benefit to 
cell growth and metabolic activity, or to the induced insulin secretion from the cells.  
These results were obtained under normoxic conditions with APA and alginate-only 
beads, as well as under long- and short-term severely hypoxic conditions with alginate-
only beads.  This finding was consistent with the results of mathematical simulations that 
noted only a small, likely experimentally undetectable, increase in cell density in PFC-
containing beads.  Simulations also indicated an increased positive effect of PFC on cells 
with a higher oxygen consumption and growth rates, but this was also modest in 
magnitude.   
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CHAPTER 4 
DUAL PERFLUOROCARBON METHOD TO NONINVASIVELY 
MONITOR DISSOLVED OXYGEN CONCENTRATION IN TISSUE 
ENGINEERED CONSTRUCTS IN VITRO* 
 
4.1  Abstract 
Noninvasive monitoring of tissue implants provides important correlations 
between construct function and the observed physiologic effects. As oxygen is a key 
parameter affecting cell viability and function, we established a monitoring method that 
utilizes 19F Nuclear Magnetic Resonance (NMR) spectroscopy, with perfluorocarbons 
(PFCs) as oxygen concentration markers, to noninvasively monitor dissolved oxygen 
concentration (DO) in tissue engineered constructs.  Specifically, we developed a dual 
PFC method capable of simultaneously measuring DO within a tissue construct and its 
surrounding environment.  In vitro studies using an NMR-compatible bioreactor 
demonstrated the feasibility of this method to monitor the DO within alginate beads 
containing metabolically active murine insulinoma βTC-tet cells, relative to the DO in 
the culture medium, under perfusion and static conditions.  The DO profiles obtained 
under static conditions were supported by mathematical simulations of the system.  The 
significance of the dual PFC system in providing critical DO measurements for 
encapsulated cells and other tissue constructs is discussed. 
 
 
* Modification of a paper published in the Biotechnology Progress (in press) 
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4.2  Introduction 
Tissue engineered constructs comprised of living cells entrapped in a 
biocompatible matrix or scaffold are promising in providing functional replacements of 
diseased tissues or organs.  Such constructs are usually highly dynamic post-
implantation, as the extent of cellular growth and remodeling, host reaction towards the 
implant, and oxygen availability at the implantation site all influence cell survival and the 
implant functional outcome.  In this context, noninvasive methods of monitoring the 
physiological state of tissue implants would prove beneficial.  Such methods would allow 
for important correlations to be drawn between construct function and the observed end 
physiologic effects, and thus provide a better understanding of the in vivo environment 
and possible mechanisms of construct failure [9, 125].  
Nuclear magnetic resonance (NMR) is a useful modality, as it can provide 
information on both the structure and function of an implant via imaging and 
spectroscopy.   Specifically, the use of the 19F nucleus is appealing, as it has a 100% 
natural isotopic abundance and a sensitivity 0.83 times that of 1H [13].  Furthermore, 
there is an absence of naturally occurring fluorine in most biological tissues, which 
eliminates the problem of interfering background signals [14].  We aim to establish a 
monitoring method that utilizes 19F NMR spectroscopy, with perfluorocarbons (PFCs) as 
oxygen concentration markers, to evaluate dissolved oxygen concentration (DO) in a 
tissue engineered pancreatic construct.   This method of monitoring works on the basis 
that the inverse spin lattice relaxation time, 1/T1, of 19F resonances from PFCs varies 
linearly with oxygen tension [100, 102].  PFCs are nontoxic, highly fluorinated 
compounds with a high capacity for dissolving respiratory gases, including oxygen [14, 
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154].  While high concentrations of PFCs could potentially be incorporated to enhance 
construct oxygenation [17, 94, 155], a low concentration of PFC is generally sufficient to 
provide the needed 19F NMR signal for monitoring.  
The importance of DO assessment in tissue implants is evident as studies have 
demonstrated a high dependence of cell survival and function on oxygen.  In vitro studies 
with beta cell lines have shown cell metabolic activity and insulin secretion being 
affected at low oxygen concentrations, although these cells appear more tolerant to 
hypoxia than intact islets [71, 156].   When islets were cultured under hypoxic conditions 
in vitro, their insulin secreting capacity was severely impaired and hypoxia-induced cell 
apoptosis or necrosis were observed [121, 157-159].  Similarly, post-transplantation, 
oxygen availability is an important determinant of graft survival and function, and 
substantial early cell death in implanted grafts due to hypoxic stress has been reported [7, 
68, 160, 161].  The rate of cellular oxygen consumption also correlates with the number 
of metabolically active cells.   Measurements with islets and cell lines demonstrated a 
proportional increase in oxygen consumption in culture with the viable cell number [9, 
122, 162-164].  In fact, the oxygen consumption rate to DNA ratio has been used to 
evaluate islet quality and to predict the transplantation outcome in diabetic nude mice 
[165, 166].    
The 19F NMR noninvasive method of monitoring has been used to measure 
oxygenation of natural, pathological, and engineered tissues.  Previous studies showed 
feasibility of this method to quantify oxygen levels in the liver, spleen, lung, and heart 
through the distribution of PFC compounds in these organs and tissues administered 
intraveneously or intraperitoneally [106, 167, 168].  The similar method of monitoring 
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has also been used extensively in the studies of in vivo tumor oxygenation, mainly to 
guide oxygen tension modulation in tumor tissue in order to improve radiotherapy 
treatment efficacy [111, 113].   Work in our laboratory proved this method successful in 
tracking the oxygenation state of βTC-tet cells encapsulated in an alginate/PFC matrix in 
vitro.  Experimentally measured DO correlated well with cell metabolic activity and 
bioenergetics, and closely matched DO values predicted by a mathematical model [9].   
In vivo, Noth et al. used this method to identify optimal implantation sites for cell 
survival in rats by performing quantitative DO measurements in PFC-containing alginate 
beads and reported very low average oxygen levels of approximately 3.4 % and 2.2 % 
(corresponding to 0.03 mM and 0.02 mM) in the peritoneal cavity and under the kidney 
capsule respectively.  They also observed a large range of oxygen levels, which varied 
over time and among different rats [108].   
As the in vivo DO can vary significantly from animal to animal but also for the 
same animal with physiologic conditions, we are pursuing the development of a dual PFC 
method for simultaneously monitoring DO in a tissue construct and its environment.  In 
this method, two PFCs with proximal chemical shifts are incorporated, one in the 
construct containing cells, which is the experimental tissue implant, and the other in cell-
free alginate beads.  The latter is used to monitor the DO level in the medium or 
implantation milieu, as equilibration of the cell-free beads with the external DO is rapid.  
Initial in vivo studies in our lab demonstrated the capability of the dual PFC method to 
simultaneously monitor DO in cell-free alginate-only, and in cell-free, poly-L-lysine 
(PLL)-coated alginate beads. As PLL is highly inflammatory in vivo, PLL-coated beads 
implanted in the peritoneal cavity of mice became covered by host cells, whereas 
 60
alginate-only beads did not.  The resulting lower intrabead DO in the PLL-coated vs. the 
alginate-only beads was detected and measured by the dual PFC method [9].   
In this study, we further characterized and proved in vitro the feasibility of the 
dual PFC method in monitoring DO within cell-containing constructs relative to the 
surroundings.  Our system consisted of murine βTC-tet insulinomas entrapped in an 
alginate matrix, which constitutes a commonly used architecture for a pancreatic tissue 
substitute.  PFCs used were perfluorotributylamine (PFTBA) and perfluoro-15-crown-5-
ether (PFCE), which differ in chemical shifts by only 9 ppm.  Each type of PFC, prepared 
in the form of an emulsion, was incorporated at 5 vol%.  Any transient partitioning of 
oxygen favoring the PFC phase does not considerably change the aqueous DO, as the 
total volume of PFC emulsion is insignificant compared to that of the aqueous phase.  
Furthermore, our previous experimental and modeling studies demonstrated that even at a 
10 vol% concentration of the PFC emulsion, the presence of PFC had only a minimal 
effect on cell growth and intrabead DO [155] (CHAPTER 3).  A similar situation exists 
with carbon dioxide, which also equilibrates between the PFC and aqueous phases, but 
with a partition coefficient lower than that of oxygen (2-4 vs. 10-20).   Studies were 
performed in an NMR-compatible bioreactor loaded with cell-free and cell-containing 
beads cultured under perfused and static conditions.  A mathematical model was also 
developed to best simulate the bioreactor culturing environment, to corroborate the 





4.3  Materials and Methods 
4.3.1  Cell Culture and Cell Encapsulation 
Murine insulinoma βTC-tet cells [142] were obtained from the laboratory of Dr. 
Shimon Efrat, Albert Einstein College of Medicine, Bronx, NY.  Cells were cultured as 
monolayers in T-175 flasks, in a 37oC, 5% CO2 humidified incubator.  Culture medium 
consisted of Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma Chemical Co., St. 
Louis MO) with 25 mM glucose, supplemented with 10% fetal bovine serum, 1% 
penicillin-streptomycin, and 1% L-glutamine to a final concentration of 6 mM, and it was 
changed every 2-3 days.  Cell monolayers that reached 80% to 90% confluency were split 
by treatment with 0.25% trypsin-EDTA (Sigma); passage number increased by one at 
each splitting.  Cells of passage number 35-45 were used in this study.   
Cells of  90% confluency were harvested by trypsin-EDTA and entrapped at a 
density of 1.0 to 7.0×107 cells/ml alginate in 2% w/v low viscosity, high mannuronic 
content alginate (LVM, NovaMatrix, Drammen, Norway) containing 50 mg/ml PFTBA 
or PFCE emulsion (see below) to produce calcium alginate beads.  Using an electrostatic 
droplet generator (Nisco Engineering Inc., Zurich, Switzerland), cells were entrapped 
according to the procedure of Stabler et al., where the alginate/cell/PFC mixture was 
extruded into a 100 mM CaCl2 solution  [143].  Some of these beads were coated with 
poly-L-lysine (PLL), and a final layer of alginate to produce alginate-poly-L-lysine-
alginate (APA) beads, used for in vivo studies.  The coating protocol was as described by 
Papas et al. [144], which was based on a protocol by Lim and Sun [145].  Beads were 
prepared at 1000 ± 200 µm in diameter for in vitro studies to avoid an excessive pressure 
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drop across the packed bed bioreactor, and at 500 ± 150 µm in diameter for in vivo 
studies.   
 
4.3.2  PFC Preparation and Incorporation in Beads 
Liquid PFTBA and PFCE were sterile-filtered through a 0.2 µm polyethersulfone 
filter (Whatman, SpringHill, UK).  Using egg yolk lecithin (Sigma) as the emulsifier, the 
PFC emulsion was prepared following a protocol adapted from Joseph et al. [146] and 
described by Gross et al. [9] (CHAPTER 3).  The emulsion was sterile-filtered through a 
0.8 µm cellulose membrane filter (Milipore, Billerica, MA), added to the sodium alginate 
solution at a concentration of 50 µg/ml and mixed thoroughly.  The PFC droplets were 
homogeneously dispersed throughout the alginate beads and the droplet size was 
approximately 1-2 µm.  
 
4.3.3  Perfusion System 
 For all in vitro experiments, beads were cultured in a 10 mm diameter × 9 in long 
NMR-compatible packed bed bioreactor (Wilmad Glass, Buena, NJ) connected to a 
computer-controlled, closed-loop perfusion circuit as described by Gross et al. [9] (Figure 
4.1(a) and (b)).  Culture medium was circulated between a medium reservoir and the 
bioreactor where the beads were held in place using a cotton plug upstream of the bed.  
The bioreactor could accommodate approximately 2 ml of beads and was positioned in 
the magnet so that the beads were within the radiofrequency coil region of the NMR 
probe.  The temperature of the medium in the bioreactor was maintained at 37oC through 
a computer-controlled air flow system and by heating the medium circulation lines.  The 
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DO in the medium entering the bioreactor was pre-equilibrated by flowing 5% CO2 
balanced with air or N2, and DO was measured using a fiber optic sensor (Ocean Optics, 
Dunedin, FL). 
 
Figure 4.1. Schematic of (a) the perfusion circuit connected to (b) the NMR-compatible 
bioreactor used to circulate culture medium and control temperature and DO levels in the 
bioreactor.  Figure adapted from Gross et al. [9]. 
 
 
4.3.4  11.7 T Magnet 
19F NMR spectra for in vitro studies were acquired using a 10 mm broadband 
probe on an 11.7 T vertical bore magnet equipped with a Bruker Avance console (Bruker, 
Billerica, MA) at the McKnight Brain Institute, University of Florida, Gainesville, FL.  
An inversion recovery pulse sequence was used to acquire T1 relaxation measurements; 
there were 12 delay times ranging from 0.01 s to 1.6 s for each T1 determination.  
Acquisition parameters for the experiments were: 5.6 kHz spectral width, 1 transient, 10 s 
relaxation delay.  Peak intensity was extracted using the area under the peak, and all T1 
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relaxation rates were determined through a 3-parameter exponential fit using Bruker 
Avance software. 
 
4.3.5  Calibration of Inverse T1 Relaxation versus DO 
Cell-free alginate beads containing 50 mg/ml PFTBA or PFCE emulsion were 
loaded in the bioreactor.  The DO in the medium entering the bioreactor was allowed to 
equilibrate at a particular level for at least 45 minutes before scanning.  This inlet 
medium DO was set equal to the intrabead DO.  T1 is independent of pH changes [169] 
but is temperature sensitive [170]; temperature was therefore tightly controlled at 37oC 
during acquisitions.  T1 relaxation measurements were obtained at five or more DO levels 





1          (4.1) 
where M is the slope (s-1 mM-1) and I is the anoxic y-intercept (s-1).  The calibration 
curves of the PFCs were generated under perfusion, at a flow rate of 6.5 ml/min, and 
under static conditions. 
 
4.3.6  Measurements of Construct DO  
βTC-tet cells were entrapped in calcium alginate at a density of 1, 3, and 7×107 
cells/ml.  Cell-free and cell-containing alginate beads, incorporating 50 mg/ml of either 
PFTBA or PFCE emulsion, were loaded in the bioreactor at a 1:1 ratio.  Following 
experimentation, beads were removed from the bioreactor and cell viability was 
examined to ensure that cells were viable during measurements.  DO values were 
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calculated using the appropriate calibration parameters established under perfusion and 
static conditions.  
 
Flow System 
For all experiments under perfused conditions, fully supplemented medium was 
circulated through the system at a flow rate of 6.5 ml/min.  Medium temperature was 
allowed to equilibrate to 37oC before any measurements were made, and the inlet DO in 
the medium was maintained at 0.18 ± 0.02 mM throughout the experiments.  The sample 
was shimmed using the FID and T1 relaxations measurements of PFCE and PFTBA were 
then obtained simultaneously.    
Static System 
Static experiments were conducted simply by stopping the flow of the medium in 
the system following the completion of a perfusion run.   The air flow system of the 
magnet maintained the culture temperature at 37oC.  The sample was shimmed using the 
FID at the beginning of each run.  T1 relaxation measurements of PFCE and PFTBA were 
then obtained simultaneously and continuously until most of the oxygen in the medium 
was depleted.  The flow of the system was then restarted to replace the medium in the 
bioreactor with nutrients and dissolved oxygen from the reservoir. 
 
4.3.7  Mathematical Modeling 
A mathematical model was developed as an extension of a previously published 
model [155] (CHAPTER 3) to simulate in vitro the difference in the average intrabead 
DO (AIDO) between the cell-free and cell-containing beads over time, under static 
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conditions.  The model simulates the fixed bed bioreactor as a closed system, where there 
is a finite volume of medium containing the beads and no transport of oxygen across the 
boundaries of this volume.  The model recognizes three compartments: the cell-
containing beads, the cell-free beads, and the liquid medium. The cell-containing and 
cell-free beads are homogeneously distributed within the medium, which is well-mixed.  
Beads are assumed to be rigid spheres.  Therefore contact points with neighboring beads 
do not affect the available area for mass transfer between the surrounding liquid and a 
bead.    Radial DO gradients are present within the cell-containing and, transiently, the 
cell-free beads.  The DO at the surface of the cell-free beads is assumed to be equal to 
that in the medium.  A boundary layer exists around the cell-containing beads, with a DO 
gradient also present in this layer.  The change in medium DO is dependent on the flux of 
oxygen across the surface of the cell-containing beads (Equation 4.2).  All equations and 
parameter values used to simulate AIDO in the cell-containing beads are the same as 
those listed in Goh et al. [155] (CHAPTER 3), except for the boundary condition.  The 
thickness of the boundary layer was an adjustable parameter evaluated by fitting 
simulations to experimental results. In cell-free beads, AIDO was calculated also from 
the same equations with X = 0.  The transient model equations were solved numerically 
using finite difference equations programmed in MatLab software.  Other model 
assumptions not explained above are listed below: 










=−=      (4.2) 
where Vb and Cb are the volume and oxygen concentration in the bulk medium, A is the 




1. There is no cell growth during the time period in the simulations; i.e., the 
encapsulated cell density remains constant.  
2. As cells cannot adhere to the alginate matrix, cells do not migrate within the 
matrix. 
3. The PFC emulsion is homogeneously distributed throughout the contiguous 
alginate matrix. 
4. Equilibration of DO between the aqueous and PFC phases at each locale in beads 
is instantaneous.   
5. The values of the model parameters, including the effective diffusivity of DO 
through the encapsulated system, remain constant over the time period of the 
simulations. 
6. The concentration gradient within the aqueous phase in beads is the only driving 
force for intra-bead oxygen diffusion. 
 
4.3.8  Statistical Analysis 
For each in vitro perfusion run, 6 or more T1 relaxation measurements were 
obtained, converted to DO via the calibration curve, and standard deviations were 
determined from these DO measurements.  The significance of DO differences between 





4.4  Results 
4.4.1  Simultaneous T1 Relaxation Measurements of the Dual PFC Bead Population  
 Figure 4.2 shows the 19F resonance peaks obtained from PFTBA and PFCE-









Figure 4.2 Representative image of 19F resonance peaks obtained from PFTBA- and 
PFCE-containing alginate beads. 
 
The spectrum was irradiated with a high-power short-duration pulse, with the transmitter 
offset set in the middle of the PFTBA and PFCE peaks of interest.  The NMR spectrum 
of PFTBA exhibits 4 resonance peaks; only 2 are displayed in the figure. T1 
measurements were based on the CF3 resonance, which is the predominant peak.  PFCE, 
on the other hand, has a single resonance peak that is approximately 9 ppm away from 
the CF3-PFTBA peak.  An inversion recovery pulse sequence was carried out within this 












4.4.2  Inverse T1 Relaxation versus DO Calibration Curves 
Figure 4.3(a) and (b) reports the calibration curves generated for PFCE and 









Figure 4.3 Calibration curves of PFTBA (CF3) (●) and PFCE (○) generated from 
different medium DO conditions under (a) perfused and (b) static conditions using an 
11.7 T magnet.  Each data point is the average of 6 T1 relaxation values with error bars 
representing their standard deviations.  
  
For both PFCs, the inverse T1 relaxation of the 19F resonances increased linearly 
with an increase in DO.  Under perfused conditions, T1 relaxation values were found to 
be consistently and significantly lower (p<0.05) relative to values obtained at the same 
DO under static conditions, which resulted in higher slopes of the calibration lines.  The 
reason for this difference is not clear; however, there is a possibility of a slight increase in 
pressure due to flow, therefore increasing the amount of DO, which would consequently 
cause a reduction in T1.  DO values under each condition were calculated from the 
respective calibration equations.   Based on independent experiments under both 
conditions, a ± 0.005 mM DO error is estimated to exist from T1 measurement and 
processing error. 
y = 2.01x + 0.50
R2 = 0.9954























y = 2.45x + 0.51
R2 = 0.993












































4.4.3  Perfused Conditions: Monitoring Steady State Construct DO under Medium 
          Flow 
βTC-tet cells were encapsulated at a density of 1, 3, and 7×107 cells/ml in calcium 
alginate beads, and were co-cultured with cell-free calcium alginate beads in a bioreactor, 
each incorporating either PFTBA or PFCE.  Table 4.1 shows the measured difference in 
DO between these two bead populations when cultured under perfused conditions.   
Table 4.1 Measured ΔDO between cell-free (medium) and cell-containing calcium 
alginate beads cultured under perfused conditions.  Standard deviations reported were 









Medium flow rate and external DO were maintained at 6.5 ml/min and 0.18 ± 
0.02 mM respectively.  As dissolved oxygen in the surrounding culture medium diffuses 
through the alginate beads very rapidly, the measured DO in the cell-free beads is 
assumed to be equal to that of the medium.  DO in beads containing cells at 1 and 3×107 
cells/ml were not significantly different than in the medium; ΔDO values were found to 
be small and within measurement error (± 0.005 mM). A measurable ΔDO was only 
obtained at a cell density of 7×107 cells/ml, where the DO in cell-containing beads was 
approximately 0.012 mM lower than in the medium.   
ΔDO (mM)
  1 x 107 cells/ml  
      Cell-free PFCE beads / Cell-containing PFTBA (n = 4) 0.0007 ± 0.0112
      Cell-free PFTBA beads / Cell-containing PFCE (n = 4) -0.0014 ± 0.0084
  3 x 107 cells/ml  
      Cell-free PFCE beads / Cell-containing PFTBA (n = 2) 0.007 ± 0.0133
      Cell-free PFTBA beads / Cell-containing PFCE (n = 2) 0.010 ± 0.0930
  7 x 107 cells/ml  
      Cell-free PFCE beads / Cell-containing PFTBA (n = 1) 0.011 ± 0.0098 
      Cell-free PFTBA beads / Cell-containing PFCE (n = 1) 0.012 ± 0.0051 
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4.4.4  Static Conditions: Monitoring Transient Construct DO in a Finite Medium 
          Volume 
Figures 4.4(a) and (b) show the DO time profiles measured by 19F NMR in the 
cell-free and cell-containing beads when cultured under static conditions.  βTC-tet cells 












Figure 4.4 DO in the (a) medium, measured using cell-free calcium alginate beads, and 
(b) cell-containing calcium alginate beads at a density of 3×107 cells/ml, as a function of 
time, under static conditions.  ΔDO measured within the two bead populations is reported 
as a function of time and medium DO in (c) and (d) respectively. Each symbol shape 
( ) represents a different preparation (total n = 3); two runs were performed with 
each preparation, and the results from each run are distinguished by the shaded (run 1) 
and open (run 2) symbol of each preparation. 
 
Total bead volume was approximately 2 ml, with a 1:1 ratio of cell-containing to 
cell-free beads.  As cells consumed oxygen, the medium DO decreased from 
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containing beads decreased over time but at a higher rate.  The measured DO values were 
consistently lower in the cell-containing beads regardless of the PFC that was 
incorporated with the cells, indicating that the observed ΔDO was not due to any PFC 
effect but to the metabolizing cells.  The ΔDO between these two bead populations was 
measurable, and ranged from 0.04 to 0.12 mM, with the difference being lower at low 
external DO (Figures 4.4(c) and (d)).   
Static experiments were also conducted for beads prepared at a cell density of 
1×107 cells/ml.  Figures 4.5(a) and (b) show the DO time profiles in the cell-free and cell-












Figure 4.5 DO in the (a) medium, measured using cell-free calcium alginate beads, and 
(b) cell-containing calcium alginate beads at a density of 1×107 cells/ml, as a function of 
time, under static conditions.  ΔDO measured within the two bead populations is reported 
as a function of time and medium DO in (c) and (d) respectively.  Each symbol shape 
( ) represents a different preparation (total n = 3); two runs were performed with 
each preparation, and the results from each run are distinguished by the shaded (run 1) 






























































Cell-free PFTBA beads and cell-containing PFCE beads


































All other experimental parameters and procedures were similar to the previous 
experiment.  As seen with the higher cell density, there was a decrease in DO in the 
medium and within the cell-containing beads over time.   This decrease, however, 
happened at a lower rate and over a longer period of time.  At this density, ΔDO ranged 
from 0 to 0.04 mM (Figures 4.5(c) and (d)).   With these smaller ΔDO values, DO errors 
(± 0.005 mM) due to T1 measurements are higher relative to the mean, resulting in a 
larger variability in the data. 
 
4.4.5  Simulated DO Profiles Under Static Conditions 
Mathematical simulations of the ΔDO profiles under static conditions were 
performed to corroborate the experimentally obtained 19F NMR measurements. A 
sensitivity analysis was carried out to evaluate the effect of the oxygen mass transfer 
coefficient in the boundary layer, kL, on ΔDO between the cell-free and cell-containing 
beads (data not shown).  A kL value of 20 cm/day was observed to be the best fit for the 
experimental data, and was used to simulate intrabead DO values.  Figures 4.6(a) and (b) 
show the experimental and simulated ΔDO profiles as a function of external DO for cell 















Figure 4.6 Mathematical simulation of the calculated ΔDO versus medium DO for beads 
cultured in a finite volume of medium. Simulated ΔDO profiles are compared to 
experimental measurements obtained for cells entrapped at a density of (a) 3×107 cells/ml 
and (b) 1×107 cells/ml.   
 
The simulated ΔDO profiles resemble those obtained experimentally, where there 
was an initial rise in ΔDO, followed by a gradual decrease over time and as the external 
DO decreased.  As expected, at 3×107 cells/ml, the simulated ΔDO achieved a higher 
maximum and had a higher rate of change relative to that at the lower cell density. 
 
4.5  Discussion 
An advantage of the dual PFC monitoring method is the chemical shift proximity 
of the fluorine resonances of PFTBA and PFCE which enables simultaneous T1 
relaxation acquisitions.  The ability to obtain simultaneous T1 measurements allows for 
the concurrent DO assessments in the construct of interest and the control.  The inclusion 
of the control group of beads to measure the surrounding DO is important because the in 
vivo environment is different among animals and may also change in the same animal 
with conditions and over time.   
Cell-free PFTBA beads and cell-containing PFCE beads











































In vitro studies using an NMR-compatible bioreactor demonstrated the initial 
feasibility of the dual PFC method.  At a sufficiently short pulse length and high magnet 
strength, reliable simultaneous T1 measurements in the dual PFC bead population were 
obtainable with negligible B1 inhomogeneity.  Under perfusion conditions, the DO in 
cell-containing beads was only minimally lower than in cell-free beads, which is 
indicative of convective transport of oxygen in beads as a result of the surrounding flow 
field.  In fact, the difference in DO between the two bead populations was measurable 
only at the highest encapsulated cell density used of 7×107 cells/ml.  On the other hand, 
under static conditions, significantly lower DO values were measured within beads 
containing metabolically active cells relative to that in the medium due to oxygen 
diffusion limitations that existed within and around these beads.  The ΔDO profiles 
obtained experimentally were consistent with a mathematical simulation of the system. 
Because of the assumptions made, the ΔDO values calculated from the model did not 
closely match those obtained experimentally; however, the compatibility of the trend and 
the rough similarity of the values strongly indicate that the experimental DO data were 
not measurement artifacts.  The static culturing conditions are more representative of the 
in vivo environment whereby cells within tissue constructs depend on passive diffusion of 
oxygen from the surroundings for survival. These in vitro studies also assisted in 
establishing the minimum cell density needed to achieve significant ΔDO values for the 






We have developed a dual PFC method that utilizes 19F NMR spectroscopy with 
PFCs as oxygen concentration markers to noninvasively monitor DO within a tissue 
construct relative to that in the culture medium.  In vitro studies proved the feasibility of 
this method to simultaneously measure DO in two distinct bead populations under 
perfusion and static conditions.  The established method was capable of distinguishing 
the oxygenation state of encapsulated cells from the DO in the surrounding medium.  
Transient changes in DO within beads cultured under static conditions were corroborated 
by mathematical simulations.   
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CHAPTER 5 
DUAL PERFLUOROCARBON METHOD TO NONINVASIVELY 
MONITOR DISSOLVED OXYGEN CONCENTRATION IN TISSUE 
ENGINEERED CONSTRUCTS IN VIVO* 
 
5.1  Abstract 
The function of an implanted tissue engineered pancreatic construct is influenced 
by many in vivo factors; however, its assessment is solely based on end physiologic 
effects.  As oxygen significantly affects construct function, we established a dual 
perfluorocarbon (PFC) method that utilizes 19F Nuclear Magnetic Resonance (NMR) 
spectroscopy, with PFCs as oxygen concentration markers, to noninvasively monitor 
dissolved oxygen concentration (DO) in βTC-tet cell-containing alginate constructs and 
in the implantation milieu.  The constructs were implanted in the peritoneal cavity of 
normal and streptozotocin-induced diabetic mice.  Using this method, the feasibility of 
acquiring real-time in vivo DO measurements was demonstrated.  Results showed that the 
peritoneal environment is hypoxic and is significantly reduced when βTC-tet cell 
constructs were implanted.  DO within cell-containing beads decreased considerably over 
time and can be correlated with relative changes in the number of viable encapsulated 
cells and/or the extent of host cell attachment.  The reduction of construct DO due to the 
metabolic activity of the βTC-tet cells was also compatible with the implant therapeutic 
function, as observed in the reversal of hyperglycemia in diabetic mice. 
 
* Modification of a paper published in Biotechnology Progress (in press)  
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5.2  Introduction 
Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease resulting 
from the destruction of insulin-producing β cells of the pancreatic islets.  Cell-based 
therapies are being explored as improved treatments relative to insulin injections, as they 
have the potential to provide tight regulation of blood glucose levels through physiologic 
secretion of insulin.  Considerable research is being done in developing tissue engineered 
pancreatic constructs where islets or other insulin secreting cells are encapsulated in 
biocompatible materials for immune protection and improved in vivo survival post-
implantation [46, 171]   
Despite advances, the challenge of engineering a long-term functional pancreatic 
construct remains, as the causes and mechanisms of implant failure are numerous and 
poorly understood [7, 64, 68, 161].   Immune rejection is a main obstacle in successfully 
transplanting allogeneic or xenogeneic cells even with the current encapsulation systems 
available [7, 67, 172]. Several investigators have reported on the infiltration of large 
numbers of host immune cells in the peritoneal cavities of rats and mice during the 
rejection of encapsulated allografts and xenografts [63, 65, 67, 173].  Rejection due to an 
immune response can be related to direct cytokine-mediated damage, not prevented by 
the encapsulation material; it could also be related to a significant inflammatory or 
fibrotic reaction towards the implant which hampers the transport of nutrients, including 
oxygen, toward the implanted cells [7, 67, 174].  The problem of limited construct 
oxygenation may be exacerbated by the low oxygen at the implantation site and, in many 
cases, the absence of vascularization around these implants [7, 160, 175].  
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Currently, assessment of the in vivo function of a pancreatic construct relies on 
measurements of blood glucose and insulin or C-peptide levels during oral glucose 
challenges [126].  A direct evaluation of the physiological state of a construct can only be 
done at the experimental end-point; therefore, to obtain information on the dynamic 
changes occurring in vivo, animals need to be euthanized and constructs retrieved at 
various time points.  Besides the large number of animals needed for such studies, the 
large inter-animal variability presents additional challenges.  Thus, there are increasing 
efforts toward developing methods for evaluating in vivo construct function on the same 
animal in real-time, in a minimally or non-invasive way [125, 126, 176, 177].  As 
construct oxygenation significantly affects cell survival and function [7, 8, 121, 159] 
monitoring of oxygen levels in pancreatic implants could provide direct information on 
their functionality.   However, most reports on the effect of hypoxia on construct function 
are limited to in vitro settings [9, 71, 121, 132, 158]; in vivo evaluation of hypoxia is 
currently performed through indirect methods post-explantation [160, 175, 178]. 
We are therefore pursuing the development of a noninvasive method of 
monitoring dissolved oxygen concentration (DO) in a tissue engineered pancreatic 
construct using 19F Nuclear Magnetic Resonance (NMR) spectroscopy, with 
perfluorocarbons (PFCs) as oxygen concentration markers.  The principle behind this 
method is the linear relationship between the inverse spin lattice relaxation time (1/T1), of 
the fluorine resonances from PFCs and oxygen tension [102].  We developed a dual PFC 
method consisting of incorporating a different PFC in cell-containing experimental beads 
and cell-free control beads; the latter group of beads was used to monitor the DO at the 
implantation milieu, as instantaneous equilibration of intrabead and external DO could be 
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assumed.  Measuring DO within the experimental implant offers an assessment of the 
metabolic activity of the cells within the construct [9].   
In a previous study (CHAPTER 4), we demonstrated the feasibility of this method 
to acquire simultaneous DO measurements within cell-containing alginate beads and in 
the culture medium.  In this study, we implemented the dual PFC method to acquire real-
time DO measurements within βTC-tet cell-containing alginate beads implanted in the 
peritoneal cavity of normal and diabetic mice.  Our goals were to obtain real-time 
measurements of construct DO, and to correlate these measurements to the physiological 
state and therapeutic function of the implant. Additionally, we investigated the effect of 
the implanted cell constructs on the peritoneal DO and compared the peritoneal DO of 
normal and diabetic mice.  The usefulness of the information provided by these studies 
on the in vivo functionality of encapsulated cell implants, and on the effect of such 
implants on host animal physiology, is discussed. 
 
5.3  Materials and Methods 
5.3.1  Cell Culture, PFC Preparation, and Cell/PFC Encapsulation 
Murine insulinoma βTC-tet cells [44] were obtained from the laboratory of Dr. 
Shimon Efrat, Albert Einstein College of Medicine, Bronx, NY.  Cells were cultured as 
monolayers in T-175 flasks, in a 37oC, 5% CO2 humidified incubator.  Culture medium 
consisted of Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma Chemical Co., St. 
Louis, MO) with 25 mM glucose, supplemented with 10% fetal bovine serum, 1% 
penicillin-streptomycin, and 1% L-glutamine to a final concentration of 6 mM, and it was 
changed every 2-3 days.  Cell monolayers that reached 80% to 90% confluency were split 
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by treatment with 0.25% trypsin-EDTA (Sigma); passage number increased by one at 
each splitting.  Cells of passage number 37-42 were used in this study.   
The PFCs used were perfluorotributylamine (PFTBA) and perfluoro-15-crown-5-
ether (PFCE).  The PFC emulsion was prepared following a protocol adapted from 
Joseph et al. [146] and described by Gross et al. [9] (CHAPTER 3).  Cells of  90% 
confluency were harvested by trypsin-EDTA and entrapped at a density of 2.0×107 
cells/ml alginate in 2% w/v low viscosity, high mannuronic content alginate (LVM, 
NovaMatrix, Drammen, Norway) containing 50 mg/ml PFTBA or PFCE emulsion (see 
below) to produce calcium alginate beads.  Using an electrostatic droplet generator 
(Nisco Engineering Inc., Zurich, Switzerland), cells were entrapped according to the 
procedure of Stabler et al., where the alginate/cell/PFC mixture was extruded into a 100 
mM CaCl2 solution  [143].  Calcium beads were coated with poly-L-lysine (PLL), and a 
final layer of alginate to produce alginate-poly-L-lysine-alginate (APA) beads, used for in 
vivo studies.  The coating protocol was as described by Papas et al. [144], which was 
based on a protocol by Lim and Sun [51].  Cells were also entrapped at a density of 2×107 
cells/ml alginate in 3% w/v LVM containing PFTBA or PFCE emulsion at 50 mg/ml to 
produce barium alginate beads.  The entrapment procedure was similar to that for calcium 
alginate beads, except that the alginate/cell/PFC suspension was extruded into a 20 mM 
or 30 mM BaCl2 solution and allowed to crosslink for 5 minutes; the beads were then 
washed 5 times with physiological saline and 3 times with unsupplemented DMEM.  The 
average diameter of the resulting APA and barium beads after washing was 500 ± 100 
µm and 700 ± 150 µm, respectively. 
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For one of the control groups (control 2, see below), encapsulated cells were 
killed through heating at 60oC for half an hour.  Cell death was confirmed through trypan 
blue (Sigma) exclusion method before implantation.   The mechanical integrity of the 
beads was determined by measuring the Young’s modulus via uniaxial compression 
using a Bose ElectroForce® 3100 apparatus (EnduraTec, Inc., Eden Prairie, MN) and 
was found not to be compromised by the heating process.[179]  
 
5.3.2  7 T Magnet 
For all in vivo measurements, 19F NMR spectra were acquired using a 16 mm 
diameter surface coil (Doty Scientific, Columbia, SC) on a 7 T horizontal bore magnet 
equipped with a Bruker Avance console (Bruker, Billerica, MA) at the Nanomedicine 
Research Institute Magnetic Resonance Laboratory, Georgia Institute of Technology, 
Atlanta GA.   An inversion recovery sequence with an 180o adiabatic pulse (hyperbolic 
secant) was used to acquire T1 relaxation measurements; there were 23 delay times 
ranging from 0.01 s to 7 s for each T1 determination.  Acquisition parameters for the 
experiments were: 2 transients, 4096 data points per free induction decay, 15 s relaxation 
delay.  Peak intensity was extracted using the area under the peak, and all T1 relaxation 
rates were determined through a 3-parameter exponential fit using Bruker Avance 
software. 
 
5.3.3  Calibration of Inverse T1 Relaxation versus DO  
Cell-free alginate beads containing 50 mg/ml PFTBA or PFCE emulsion were 
loaded in a 50 ml centrifuge tube containing physiologic saline.  The solution was 
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bubbled with nitrogen, air or oxygen at 37oC and atmospheric pressure for at least 45 
minutes to allow for equilibration, then sealed and placed on the surface coil.  
Temperature was maintained with a water bath that pumped heated water through tubing 
wrapped around the centrifuge tube.  T1 relaxation measurements were obtained and 





1          (5.1) 
 
5.3.4  Animals and the Induction of Diabetes 
All experiments were carried out in accordance with protocols approved by the 
Georgia Tech Animal Care and Use Committee.  Balb/c mice were obtained from 
Jackson Labs (Bar Harbor, ME) and housed under specific pathogen-free conditions in 
the animal facility at Georgia Tech.  Six-week old mice were used for subtherapeutic 
studies.  Ten-week old mice were made diabetic through multiple i.p injections of 210 
mg/kg of streptozotocin (Sigma), dissolved in sodium citrate buffer (pH 4.5) (Sigma).  
Mouse blood glucose levels and body weights were monitored daily.  Blood glucose 
concentrations were measured in blood samples collected from mice tail veins by 
TRUEtrack glucose monitors (CVS, Woonsocket, RI).  Mice were considered diabetic 
when their blood glucose levels were above 350 mg/dl for 2 consecutive days.  Mice that 
had blood glucose levels above 250 mg/dl for 2 consecutive days after construct 





5.3.5  Construct Implantation and DO Measurements 
This study is divided into two parts; subtherapeutic and therapeutic study where 
the constructs were implanted in normal mice and in STZ-induced diabetic mice, 
respectively.  The alginate beads were implanted in the mouse peritoneal cavity through a 
simple injection.  For all studies, the PFC emulsion was incorporated at a concentration 
of 50 mg/ml, and βTC-tet cells were entrapped at a density of 2×107 cells/ml.  The groups 
of mice and types of implant are as listed in Table 5.1 below: 
 
Table 5.1 Types and volumes of implanted beads in different groups of mice 
Part I - Subtherapeutic Study
Study 1
     Control Normal (n = 2) 0.4 ml of cell-free PFTBA calcium alginate beads and 0.4 ml of cell-free PFCE calcium alginate beads
     Experimental Normal (n = 7) 0.6 ml of cell-free PFTBA calcium alginate beads and 0.2 ml of cell-containing calcium APA beads
Study 2 
     Control Normal (n = 4) 0.4 ml of cell-free PFTBA barium alginate beads and 0.4 ml of cell-free PFCE barium alginate beads
     Experimental Normal (n = 14) 0.6 ml of cell-free PFTBA barium alginate beads and 0.2 ml of cell-containing barium alginate beads
Part II: Therapeutic Study
     Control 1 - Normal (n = 4), Diabetic (n = 6) 0.7 ml of cell-free PFTBA barium alginate beads and 0.3 ml of cell-free PFCE barium alginate beads
     Control 2 - Normal (n = 3), Diabetic (n = 4) 0.6 ml of cell-free PFTBA barium alginate beads and 0.2 ml of dead cell-containing PFCE barium alginate beads




Two mice were also implanted with cell-free, PFC-free, alginate beads to ensure 
that there was no 19F background signal and that the resonances observed were from the 
PFCs.   PFC-containing beads were implanted at different volumes so that sufficient 
NMR signal can be obtained; this does not affect DO values.   
Experimental normal mice that had blood glucose levels below 100 mg/dl were 
given drinking water containing 1 mg/ml tetracycline (Sigma) with 1.5% (w/v) sucrose 
(Sigma) to inhibit cell proliferation.  Experimental diabetic mice were given drinking 
water containing 4 mg/ml tetracycline (Sigma) with 1.5% (w/v) sucrose (Sigma) starting 
from Days 1 to 4 until the end of the experiment.  The tetracycline water was replaced 
every 2 days.  βTC-tet undergoes growth arrest in the presence of tetracycline [44]. 
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During NMR scans, mice were anesthesized in 1.5% isoflurane in oxygen flowing 
at 1.5 l/min, and kept at 37oC with a warming pad. 
 
5.3.6  Post-explantation Studies 
Following NMR scans, experimental mice were euthanized on Days 4, 8 and 16, 
and control normal and diabetic mice were euthanized on Day 16 and Day 2 respectively.  
Beads were explanted via peritoneal lavage with Dulbecco’s Phosphate-Buffered Saline 
(MediaTech, Manassas, VA).   Bead integrity was visualized by light microscopy.  Host 
cell attachment and cell growth were evaluated through histology, where beads were 
fixed in 2% glutaraldehyde (Sigma), embedded in paraffin, sectioned, and stained with 
hematoxylin/eosin (H/E).  Cell viability was analyzed through a live/dead assay.  Living 
and dead cells were stained with calcein-AM (excitation: 488 nm/emission: 500-530 nm) 
and ethidium homodimer (excitation: 543 nm / emission: 560 nm) (Invitrogen, Eugene, 
OR) and observed using a confocal microscope (LSM 510 META, Zeiss, Maple Grove, 
MI).   
To evaluate β-cell function, retrieved beads were subjected to an insulin secretion 
test, where the cell-free and cell-containing bead mixture was cultured in basal medium 
(0 mM glucose, unsupplemented DMEM) for 1 hour and then transferred to stimulating 
medium (16 mM, fully supplemented DMEM) for 30 minutes.  Medium samples 
withdrawn at the start and end of each basal and stimulation period were stored at -80oC 
for later assays.   Insulin concentration in collected samples was assayed using mouse 
insulin ELISA (Mercodia, Uppsala, Sweden) and absorbance was measured at 450 nm 
wavelength using a Spectra Max Plus Plate Reader (Molecular Devices, Sunnyvale, CA).  
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As the explanted bead samples used were random mixtures of cell-free and cell-
containing beads, the number of βTC-tet cells could not be quantified; therefore, 
secretion results were reported only as positive when a stimulated insulin secretion 
response was detected.   
 
5.3.7  Statistical Analysis 
All data were analyzed using Minitab software (Minitab, Inc., State College, PA).  
A total of 3 T1 relaxation measurements were obtained from a single mouse and DO was 
determined from the average of these values.  DO data were reported as the mean of the 
average DO values from the mice scanned on a particular day ± standard deviation of the 
averages.  The significance of DO differences between groups and days were evaluated 
using one-way analysis of variance (ANOVA) with General Linear Model. 
 
Part I: Subtherapeutic Study 
5.4  Results 
5.4.1  Simultaneous T1 Relaxation Measurements of the Dual PFC Bead Population  
The inverse T1 relaxation measurements of 19F resonances increased linearly with 
DO.  Table 5.2 summarizes the linear fit parameters for the two PFCs; these parameters 
were used for DO determinations from T1 measurements of the implanted constructs.  
Table 5.2 Slope (M) and y-intercept (I) of the linear calibration curves correlating the 
inverse T1 relaxation to DO.  Calibrations were performed for PFTBA and PFCE under 






M (s-1 mM-1) I (s-1) Correlation coefficient, R2
PFTBA 2.04 0.44 1.000
PFCE 2.10 0.85 0.999
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Figure 5.1 shows typical 19F NMR spectra acquired from an anesthetized mouse 
implanted with (a) cell- and PFC-free barium alginate beads, and (2) cell-free, PFTBA 
and PFCE-containing barium alginate beads. 
Figure 5.1 19F resonance peaks obtained from mice implanted with (a) cell- and PFC-free 
alginate beads and (b) cell-free, PFC-containing alginate beads. (c) Representative 3-
parameter exponential fit of a typical inversion recovery experiment for T1 determination. 
x-axis: relaxation delay time (s), y-axis: integrated peak area 
 
When mice were placed under anesthesia, 19F NMR measurements obtained 
yielded a flat baseline over the spectral region of interest, although 2 resonance peaks 
identified to be due to isoflurane were observed.  The isoflurane peaks did not interfere 
with those of PFTBA or PFCE as seen in mice that were implanted with PFC-containing 
beads.  Similar to in vitro observations, the PFTBA-CF3 peak was approximately 9 ppm 
away from the single PFCE peak; the chemical shift proximity of these two peaks 
allowed for simultaneous T1 acquisitions.  All the exponential fits of the inversion 
recovery experiment for T1 acquisitions were good, as seen in a representative fit shown 
in Figure 5.1(c).  This indicates that there was a narrow distribution of DO values in the 
beads implanted in the peritoneal cavity.  







5.4.2  Monitoring in vivo DO and Evaluation of Explanted Constructs 
Study1: Calcium Alginate-PLL-Alginate (APA) Cell-containing Implant 
APA beads containing βTC-tet cells/PFCE were implanted at subtherapeutic 
levels in the peritoneal cavity of experimental normal mice.  Cell-free PFTBA calcium 
alginate beads were co-implanted to track the oxygen levels at the surrounding peritoneal 
environment.  These DO values were also compared to those measured in the peritoneal 
cavity of control mice implanted with cell-free PFTBA and PFCE calcium alginate beads.  
Figure 5.2 shows the DO measurements obtained through 19F NMR within these two 
bead populations in the experimental and control mice, along with images of explanted 


















Figure 5.2 DO within cell-free calcium alginate beads implanted in the peritoneal cavity 
of control mice (n = 2 on all days); and DO within cell-free calcium alginate and cell-
containing APA beads implanted in the peritoneal cavity of experimental mice (n = 4, 4, 
5, 3, 3 for Days 1, 4, 8, 12, 16 respectively).  Also shown are representative images of 
explanted cell-free and cell-containing beads, examined through light microscopy and 
histology.  Histological image of the cell-free PFTBA bead is marked with an arrow.  
#p<0.05, compared between cell-free and cell-containing beads at a time point, *p<0.05, 
compared between experimental and control mice, the latter with nested PFC groups, 














Control Mice - Cell-free PFTBA beads
Control Mice - Cell-free PFCE beads
Experimental Mice - Cell-free PFTBA beads


























Measured DO within the implanted beads fluctuated considerably between 
acquisitions.  DO in the peritoneal cavity of the control mice, measured using cell-free 
PFC beads, were found to be 0.09 ± 0.068, 0.07 ± 0.019 and 0.10 ± 0.023 mM on Days 1, 
8 and 16 respectively.  It is worthwhile to note that the actual peritoneal DO might be 
slightly lower than reported here due to the fact that mice were breathing isoflurane in 
100% oxygen during NMR scans.   
On Day 1, DO within cell-containing beads and the surrounding peritoneal cavity, 
measured using cell-free beads, were observed to be 0.053 ± 0.010 and 0.068 ± 0.008 
mM respectively in experimental mice.  These values were statistically similar to those 
obtained in control mice implanted with only cell-free beads.  The DO in the cell-
containing beads and the surrounding peritoneal cavity decreased over the first 8 days to 
significantly lower levels when compared to Day 1 (p<0.05).  These DO values were also 
statistically lower than the peritoneal DO measured in control mice, and remained as such 
until the end of the experiment.  On Day 16, the DO within the cell-containing beads was 
statistically lower than the surrounding peritoneal DO in experimental mice (0.033 ± 
0.008 mM vs. 0.061 ± 0.014 mM, respectively). 
All beads explanted from control and experimental mice were intact when 
visualized under light microscopy.  Histological analysis and live/dead staining showed 
some initial cell growth the first 8 days, and that cell-containing APA beads exhibited 
host cell attachment which worsened over time.  From Day 8 to Day 16, however, there 
were no further cell growth and the extent of host cell attachment remained the same.  
Co-implanted cell-free alginate beads were clear of overgrowth on Day 4.  While a few 
adherent cells were detected around these beads on Days 8 and 16, generally less than 
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10% of the bead surface area was covered.  All cell-free alginate beads implanted in the 
control mice were clear of host cell attachment.   Insulin secretion was detected in 
explanted beads from experimental mice on all days, verifying the presence of viable 
βTC-tet cells (Results shown in Figure A4.1 in Appendix IV).   . 
 
Study 2: Barium Alginate Cell-containing Implant 
Because PLL is known to induce in vivo host responses, as also observed in this 
study, we switched to using barium alginate beads, which have been found to be a more 
biocompatible material in comparison [62, 65].  Similar experiments were carried out 
with βTC-tet cells entrapped in barium alginate beads with PFCE, and co-implanted with 
cell-free PFTBA barium alginate beads.  Control mice were implanted with cell-free 
PFTBA and PFCE barium alginate beads.  Figure 5.3 shows the DO measurements 
obtained through 19F NMR within these two bead populations in the two groups of mice, 






























Figure 5.3  DO within cell-free barium alginate beads implanted in the peritoneal cavity 
of control mice (n = 4, 2, 2, 4 on Days 1, 8, 9, 16); and DO within cell-free and cell-
containing barium alginate beads implanted in the peritoneal cavity of experimental mice 
(n = 7, 4, 5, 5, 6, 4 for Days 1, 4, 8, 9, 12, 16 respectively). Also shown are representative 
images of explanted cell-free and cell-containing beads, examined through light 
microscopy and histology. Histological image of the cell-free PFTBA bead is marked 
with an arrow.  *p<0.05, compared between experimental and control mice, the latter 
with nested PFC groups, analyzed using one-way ANOVA with General Linear Model. 
 
DO in the peritoneal cavity of control mice, measured using cell-free PFC beads, 
were found to be 0.068 ± 0.014, 0.047 ± 0.015, 0.096 ± 0.018 and 0.072 ± 0.025 mM on 
Days 1, 8, 9 and 16 respectively.  In experimental mice, the DO within cell-containing 
beads and the surrounding peritoneal cavity were measured to be 0.046 ± 0.006 mM and 
0.043 ± 0.011 mM respectively on Day 1, and were observed to gradually decrease over 
time.   When compared to Day 1, this decrease was only significant on Day 16 (p<0.05), 
where DO values were 0.031 ± 0.029 mM and 0.024 ± 0.004 mM respectively.  On Days 
1, 9 and 16, the DO in the cell-containing beads and the surrounding peritoneal cavity in 
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There was no difference between the two bead populations implanted in the experimental 
mice on any of the days when measurements were performed.  
The majority of the explanted beads from both control and experimental mice 
were intact when observed microscopically, although a few broken beads were found 
occasionally.  Within the experimental time frame, all cell-free and cell-containing beads 
were clear of host cell attachment.  Histological analysis and live/dead staining showed 
insignificant cell growth during the first 8 days, and the measured insulin secretion was 
low during this period of time.  On Day 16, however, there was a marked increase in cell 
number and a significantly higher amount of insulin secreted during glucose stimulation 
(Results shown in Figure A4.2 in Appendix IV).      
 
5.5  Discussion 
Perfluorocarbons have been increasingly used as physiological markers of tissue 
oxygenation in 19F NMR.  The high fluorine content of these compounds make them 
good imaging contrast agents or concentration markers for dissolved oxygen, as a 
relatively low concentration of PFC is usually sufficient to achieve good signal 
intensities.   Furthermore, most PFCs are safe and biocompatible, thus making them 
suitable for in vivo studies [13, 180, 181].  Zimmermann et al. evaluated the metabolic 
activity of mouse L-cells co-cultured with PFTBA up to 70%, and observed no apparent 
cytotoxicity when compared to a control group [109].  When entrapped in alginate beads, 
the PFC emulsion is stable, thereby preventing it from being eliminated from the body 
and allowing for long term monitoring studies [9].  In this study, the 19F signal obtained 
from the PFCs on Day 16 was observed to be comparable to that obtained on Day 1, 
 93
indicating that the majority of the beads were still intact and that the PFC emulsion was 
stable.  While this study was only 16 days long, other researchers have been able to detect 
19F signal of entrapped PFC over three months post-implantation [108, 109].  
In this study, a single average T1 value was obtained from the sum of the signal 
intensities from all volume elements across the sample in the peritoneal cavity.  All the 
exponential fits for the T1 values were good, indicating a narrow distribution of intrabead 
DO values for a particular animal at a time point.  Although one could obtain the DO 
distribution within the peritoneal cavity by applying one or two-dimensional chemical 
shift imaging, construction of such oxygen profiles requires long acquisition times and 
high concentrations of PFC for sufficient signal.  As we are ultimately concerned with 
evaluating the function of the entire implant over time, the average DO measurements 
used in this study were sufficient for this assessment.   
The dual PFC method was proven capable of tracking both the DO in the cell-
containing beads and the peritoneal DO over 16 days through 19F NMR.  The peritoneal 
cavity was found to be hypoxic, with oxygen levels varying significantly over time.  This 
observation was consistent with other studies, including those of Noth et al. and Gross et 
al. who reported that peritoneal DO ranged from -0.007 to 0.24 mM in rats [108] and 0.02 
to 0.27 mM in mice [9], respectively.  Studies with APA beads indicated gradual cell 
growth and host cell attachment around the beads over the first 8 days; these observations 
were compatible with the decrease in DO within the cell-containing beads. The lack of 
further cell growth and host cell attachment could explain the DO stabilizing within these 
beads from Day 8 onwards.  On the other hand, cell growth in barium alginate beads was 
slow the first 8 days; this delayed growth pattern being similar to that observed in βTC3 
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cells entrapped in high guluronic acid content alginate [182].  On Day 16, there was a 
marked increase in the viable cell number and amount of secreted insulin, which was also 
reflected in the significantly lower DO within the cell-containing beads when compared 
to Day 1.  It should be noted that although the therapeutic function of the implanted 
constructs was not evaluated in this study, the measured DO and observed cell growth 
appeared consistent with the changes in the overall mouse blood glucose levels.  
Specifically, mice implanted with APA beads approached hypoglycemia within the first 
few days post-implantation, whereas mice implanted with barium alginate beads 
remained normal within the first 10 days, but started to approach hypoglycemia thereafter 
(data not shown).   
For both studies with APA and barium alginate beads, a lower peritoneal DO was 
measured in the experimental mice implanted with βTC-tet cells when compared to the 
peritoneal DO of the control mice.  This suggests that a considerable amount of oxygen 
was being consumed by the metabolically active βTC-tet cells, and possibly also by the 
peritoneal host cells surrounding the APA beads.  Although inflammatory reaction 
towards the barium alginate beads was not observed, host cells could still be recruited to 
the implantation site as observed by Safley et al. who reported a significant increase in 
the number of host cells infiltrating the peritoneal cavity after one week following 
transplantation of xenogeneic adult porcine islets entrapped in barium alginate [65].  In 
this study, however, allogeneic cells were implanted in normal mice.   The decrease in the 
peritoneal DO is also likely to be more pronounced in diabetic mice, as we would expect 
a higher metabolism and oxygen consumption by the implanted β cells to meet the 
demands for insulin secretion. Presumably then, through this dual PFC method of 
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monitoring, correlations between construct oxygenation and the achieved therapeutic 
effects can be established.  It is also reasonably expected that this monitoring approach 
can be adapted for other implantation sites, or other tissue engineered constructs besides 
encapsulated cells. 
 
Part II: Therapeutic Study 
5.6  Results 
5.6.1  Correction of Diabetes in STZ-Induced Diabetic Balb/c Mice 
The construct therapeutic function was evaluated through daily determinations of 
random blood glucose levels in mice.  Figure 5.4 shows blood glucose concentrations of 
diabetic mice implanted with encapsulated βTC-tet cells (experimental), cell-free beads 










Figure 5.4 Blood glucose levels of control 1D and 2D mice receiving cell-free beads (n = 
6) and dead cell-containing beads (n = 4), respectively, and of experimental mice 
receiving βTC-tet cell-containing beads (n = 9 to 17).  On Day 4, 5 experimental mice 
were euthanized and on Day 8, 3 mice experimental were euthanized.   
 
 Implantation of βTC-tet cells corrected hyperglycemia within 3 days and 
maintained normoglycemia in the mice until euthanasia, indicating that the constructs 



































cell proliferation, the mice did not become hypoglycemic at later time points but blood 
glucose levels stabilized within normal ranges.  There was a 7% increase in the average 
body weight of these mice within 16 days.  Control diabetic mice that received cell-free 
beads and dead cell-containing beads remained hyperglycemic and were euthanized two 
days post-implantation. 
 
5.6.2  Monitoring DO in the Tissue Construct and the Peritoneal Cavity 
STZ-induced diabetic mice (experimental) were implanted with βTC-tet cell-
containing PFCE beads and cell-free PFTBA beads in the peritoneal cavity, and DO 
measurements within these two bead populations were obtained over time.  These DO 
values were compared to those measured in cell-free PFCE and PFTBA beads, implanted 
in normal and diabetic mice (controls 1N and 1D, respectively), and in dead βTC-tet cell-
containing PFCE beads and cell-free PFTBA beads, also implanted in normal and 
diabetic mice (controls 2N and 2D, respectively).   
Figure 5.5 shows the 19F NMR-acquired DO in beads from the experimental and 


























Figure 5.5  DO measurements in cell-containing PFCE beads and cell-free PFTBA beads 
implanted in experimental mice (n = 8 on Day 1, n = 9 on all other days), in cell-free 
PFCE and PFCE beads implanted in control 1N mice (n = 4), and in dead cell-containing 
PFCE beads and cell-free PFTBA beads implanted in control 2N mice (n = 3).  **p<0.05, 
compared between experimental and control 1N mice, the latter with nested PFC groups; 
*p<0.05, compared between experimental and control 2N mice; ##p<0.05, compared to 
Day 1 in cell-free beads in experimental mice; #p<0.05, compared to Day 1 in cell-
containing beads in experimental mice.  All comparisons analyzed using one-way 
ANOVA with General Linear Model.  
 
The average DO in the peritoneal cavity of control 1N mice ranged from 0.065 to 
0.073 mM during the Day 1 to 16 time period, with no statistical differences found 
between any of the days.   The peritoneal DO of control 1D mice (n = 6) was also 
measured on Days 1 and 2 and found to be 0.088 ± 0.012 and 0.079 ± 0.016 mM, 
respectively; the DO on Day 1 was not different from that in control 1N mice.  
One day post-implantation, the peritoneal DO in experimental mice was 0.065 ± 
0.03 mM and in the βTC-tet cell-containing beads 0.063 ± 0.012 mM; these were not 
statistically different.  The DO in the cell-containing beads decreased over time, and on 
Day 8 became and stayed significantly lower than the Day 1 value until the end of the 
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experiment.  The peritoneal DO was also significantly lower on Day 8 than on Day 1.  
The DO in the cell-containing beads was comparable to the peritoneal DO on all days in 
the experimental mice.  Notably, the DO within the cell-containing beads and the 
peritoneal cavity in experimental mice were both significantly lower than the peritoneal 
DO in control 1N mice on Days 8 and 16.  
To assess whether the lowered DO observed in experimental mice was due to the 
metabolic activity of the implanted βTC-tet cells, or whether recruited host immune cells 
also played a role, measurements were obtained from control 2N mice implanted with 
cell-free and dead βTC-tet cell-containing beads.  Average DO values in the dead cell-
containing PFCE beads ranged from 0.075 to 0.086 from Day 1 to 16, with no statistical 
differences between any of the days.  DO measurements were also obtained from the 
same type of beads implanted in control 2D mice (n = 4) on Days 1 and 2, and found to 
be 0.067 ± 0.014 and 0.072 ± 0.016 mM, respectively; the DO on Day 1 was not different 
than that in control 2N mice.  DO measurements in the dead cell-containing beads were 
comparable to the surrounding peritoneal DO on all days for all mice.  More importantly, 
these DO measurements were also comparable with the peritoneal DO in control 1N 
mice, but significantly higher than the DO measured in beads implanted in experimental 
mice. 
 
5.6.3  Evaluation of the Physiological State of the Tissue Construct 
Figure 5.6 shows representative images of beads explanted from control 1N and 
2N mice on Day 16 and from experimental mice on Days 4, 8, and 16.   
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Figure 5.6 Light micrographs (4×), histological analysis (10×), and live/dead staining 
(10×) of representative beads explanted on Day 4 (n = 5), Day 8 (n = 3), and Day 16 (n = 
9) from experimental mice and beads explanted on Day 16 from control 1N mice (n = 3) 
and control 2N mice (n = 4). 
 
Explanted beads from all groups were intact when observed microscopically, 
although a few broken beads were found occasionally.  Live/dead staining and 
histological examination showed that beads from experimental mice contained viable 
βTC-tet cells on all explantation days, and that both cell-free and cell-containing beads 
were clear of host cell attachment throughout the experimental time period.  Some initial 
cell growth was observed the first week post-implantation; insignificant cell growth was 
observed thereafter.  Encapsulated βTC-tet cells were also functional on all explantation 
days, as detected by an increase in insulin release to an in vitro glucose stimulation test 
(Results shown in Figure A4.3 in Appendix IV).  With beads explanted from control mice 
2N, no live βTC-tet cells were detected by live/dead staining and histology; also, when 
beads were subjected to an in vitro glucose stimulation test, no insulin was detected, 
confirming that the cells were indeed nonfunctional.  Similar observations were made 
with beads explanted from the control mice 1D and 2D on Day 2 (images not shown).  
Day 4 Day 8 Day 16 
Experimental Control 2 Normal 
Day 16 Day 16 
Control 1 Normal 
 100
5.7  Discussion 
Tissue engineered pancreatic constructs have the potential to provide tight 
glycemic control in IDDM patients.  The peritoneal cavity is a plausible implantation site 
as it can easily accommodate these constructs [183].  However, with beads implanted in 
the peritoneal cavity, the supply of oxygen to the cells occurs through passive diffusion 
only, and a host cellular response could further deplete oxygen within the encapsulation 
device [7].  As a multitude of studies have reported on compromised insulin secretory 
response of islets or transformed β cell lines under in vitro low oxygen conditions [8, 
121, 132, 158] and on early post-implantation graft failure as a result of hypoxic stress [7, 
68, 160] the ability to monitor construct oxygenation is evidently important.  
While noninvasive evaluation of oxygen supply at different implantation sites has 
been performed using cell-free PFC constructs [109, 184], our work involves the 
investigation of oxygen levels within functional, cell-containing pancreatic implants.  In 
this study, we demonstrated that in vivo real-time oxygen measurements within a tissue 
engineered pancreatic construct, implanted in a diabetic mouse model, can be obtained 
noninvasively through 19F NMR.  Furthermore, the design of the dual PFC method 
enabled simultaneous tracking of DO within the construct and at the implantation milieu.  
Measurements confirmed the peritoneal cavity of normal mice to be hypoxic, with DO 
values comparable to those obtained previously (Part I) and reported in literature [9, 184]  
Equivalent peritoneal DO values were also obtained in diabetic mice within two days 
post-implantation.  
In experimental mice implanted with encapsulated βTC-tet cells, DO 
measurements in the cell-containing beads appeared to correlate with the relative change 
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in the number of viable cells examined post-explantation, as observed in the decrease in 
DO with cell growth over time.  This reduced DO at later time points can be attributed to 
a higher oxygen consumption by βTC-tet cells, as there was no host cell attachment to 
any of the beads.   Notably, the implantation of viable encapsulated cells resulted in a 
significant reduction of the peritoneal DO relative to mice that did not receive viable cell 
implants.  However, even though there was no inflammatory reaction to the beads, a 
cellular immune response could still be elicited due to antigens secreted by the βTC-tet 
cells.  Shed antigens can combine with antibodies to form complexes which bind to the 
receptors on peritoneal macrophages [63, 67].  If the antigen load is sufficiently high, the 
recruitment of host peritoneal cells could be significant, possibly contributing to the 
observed reduction in peritoneal DO.    
To assess this possibility, an antigenic load from a similar encapsulation system 
was introduced by implanting beads containing dead βTC-tet cells in control 2N and 2D 
mice; dead cells would eventually lyse and hence release antigens.  Inevitably, control 2D 
mice which received such nonfunctional cell implants remained hyperglycemic and were 
euthanized two days post-implantation.    In control 2N, the DO within dead cell-
containing beads and the peritoneal DO did not decrease over time, but remained 
comparable to the peritoneal DO of control 1N mice at all measured time points.   
Therefore, these results indicate that the observed reduction in construct and peritoneal 
DO in experimental mice was caused by the metabolic needs imposed by the viable 
implant.  Although unlikely, the possibility of a higher recruitment of host cells by the 
viable βTC-tet cells relative the dead cells cannot be excluded.  Nevertheless, regardless 
of its precise cause, the lowered DO has significant implications with respect to implant 
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survival and function.  This is especially critical in situations in which a higher number of 
implanted cells may be needed, such as with xenografts or with larger animal models.[64]    
Contrary to our in vitro observations [185], in vivo measurements showed the DO 
within beads containing metabolically active cells to be equivalent to the surrounding 
peritoneal DO at all measured time points.  This might be due to the lower magnet 
strength (7 T versus 11.7 T) and smaller sample volume used for the in vivo studies   
The analysis of construct DO in relation to implant function is important, as the 
presence of viable islets or transformed β cells does not ascertain insulin secretory 
capacity [71, 121, 186].  In this study, the encapsulated βTC-tet cells survived well in the 
peritoneal cavity and the number of implanted cells was sufficient to restore 
normoglycemia in diabetic mice.  Despite the reduced DO in the cell-containing beads in 
experimental animals, sufficient insulin secretory capacity was apparently maintained, as 
normoglycemia was maintained in these mice.  This can be attributed to the high 
tolerance of transformed β cell lines to hypoxia; for instance, Papas et al. reported insulin 
secretion of βTC3 being compromised only at an oxygen levels below 0.009 mM [71].  
The observed implant therapeutic function was compatible with the overall reduction in 
DO within constructs containing metabolically active βTC-tet cells.   
19F NMR is a useful modality that can be utilized to obtain in vivo quantitative 
DO measurements within implants without relying on indirect measurement methods.  
Correlations established between construct DO and the observed end physiologic effects 
may provide a better insight into the in vivo factors that affect implant function and assist 
in the development of a long-term functional tissue engineered pancreatic construct for 
diabetes treatment. 
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5.0  Conclusions 
Using 19F NMR, the dual PFC method of monitoring allows for real-time, 
noninvasive in vivo tracking of DO within a tissue engineered pancreatic construct and at 
the implantation milieu.   Measurements showed that the peritoneal oxygen environment 
is variable and hypoxic in normal and diabetic mice.    In APA beads, construct DO was 
reduced over time and correlated with cell growth and host cell-attachment examined 
post-explantation.  Barium alginate beads did not elicit inflammatory responses within 
the experimental time period; the obtained construct DO measurements can be used for 
the detection of the relative changes in the number of viable cells within the construct.  In 
all studies, the implantation of metabolically active βTC-tet cells significantly reduced 
the surrounding peritoneal DO.  The overall reduction in construct DO due to the 
metabolic activity of βTC-tet cells was compatible with implant function as observed in 





CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1  Conclusions 
A major issue in tissue engineering a pancreatic construct is ensuring sufficient 
oxygenation of the cells within the construct to maintain cell viability and function.  As 
oxygen is always the limiting nutrient, the rate or extent of oxygen consumption is a good 
indicator of the number of metabolically active cells.   Using alginate-encapsulated βTC-
tet cells as our model system, we explored the use of PFCs to (1) improve cell viability 
and function by increasing construct oxygenation and (2) develop a method of monitoring 
oxygen levels within the construct and its surroundings through 19F NMR.   
In CHAPTER 3 of this thesis, the effects of PFTBA on βTC-tet cells encapsulated 
within calcium alginate beads were investigated through experimental studies and 
mathematical simulations.  The addition of 10 vol% PFTBA emulsion into the construct 
did not significantly increase cell growth and metabolic activity, or the induced insulin 
secretion from the cells under both normoxic and short- and long-term hypoxic 
conditions.  Mathematical simulations showed that although the presence of PFC 
improved the DO effective diffusivity and the overall construct oxygenation, there was 
only a slight, likely experimentally undetectable, increase in the cell density supported by 
the presence of PFC.   Furthermore, the capacity of PFC to provide oxygen to the 
aqueous phase of the construct when exposed to hypoxic conditions was also minimal.  
Therefore, the incorporation of PFC appeared to have limited beneficial effects on the 
encapsulated cells.  
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The incorporation of PFC also enabled construct DO measurements through T1 
relaxation acquisition of the fluorine resonances.  We established a dual PFC method that 
utilizes 19F NMR spectroscopy, with PFCs as oxygen concentration markers, to 
noninvasively monitor DO within a tissue implant relative to that in the surrounding 
environment.  The dual PFC method consisted of the incorporation of each of the PFCE 
and PFTBA emulsion, either with cells encapsulated in alginate beads or in cell-free 
alginate beads.  The latter group of beads was used to monitor the DO in the culture 
medium or at the implantation milieu.  PFCE and PFTBA have chemical shifts that are 9 
ppm apart from each other, which enabled simultaneous T1 acquisitions for DO 
determination within the beads.   As reported in CHAPTER 4 of this thesis, in vitro 
studies using an NMR-compatible bioreactor demonstrated the feasibility of this method 
to simultaneously obtain DO measurements within alginate beads containing βTC-tet 
cells and in the culture medium. Under perfusion conditions, the steady state DO within 
the cell-containing beads was only minimally different from the surrounding medium 
except at a high encapsulation density of 7×107 cells/ml.  This is indicative of the 
convective transport of oxygen due to the surrounding flow field.  Under static 
conditions, however, significantly lower DO levels were measured within the cell-
containing beads when compared to the surrounding medium; this demonstrates the 
capability of the method to track the oxygenation state of constructs containing 
metabolically active cells.  Apart from proof-of-concept, the in vitro studies assisted in 
the optimization of the experimental parameters of the method, which was subsequently 
used for in vivo studies.   
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In CHAPTER 5 of this thesis, we reported on the monitoring of DO levels within 
the dual PFC bead population implanted in the peritoneal cavity of both normal and 
streptozotocin-induced diabetic mice.  Two types of implants were examined; calcium 
alginate-poly-L-lysine-alginate (APA) beads and barium alginate beads, both containing 
βTC-tet cells.   Using 19F NMR, the dual PFC method allowed for real-time, noninvasive 
in vivo tracking of DO within the cell-containing beads and the peritoneal surroundings 
for 16 days.  In both normal and diabetic mice, measurements from the cell-free beads 
showed that the peritoneal oxygen environment is variable and hypoxic, and is 
significantly lower in the presence of viable βTC-tet cells.  DO within the cell-containing 
APA beads decreased with the extent of cell growth and host cell attachment examined 
post-explantation.  When host cell attachment was absent, as seen with barium alginate 
beads, the obtained DO measurements correlated with the relative changes in the number 
of viable cells within a construct.  The reduction of construct DO due to the metabolic 
activity of the βTC-tet cells was also compatible with the implant therapeutic function, as 
observed in the maintenance of normoglycemia in mice.  
The established correlations between in vivo DO measurements and the observed 
end physiologic effects demonstrated the reliability and applicability of the developed 19F 
NMR method to noninvasively monitor implant function.  Using this method, the effects 
of the βTC-tet cell implant on host animal physiology were observed.  Of particular 
importance is the significantly reduced peritoneal DO in the presence of a viable implant.  
This indicates a possibility of hypoxic stress under implantation conditions such as when 
using cells with a high oxygen demand or when a high number of implanted cells is 
needed. Ultimately, this method can be used to provide a better insight into the in vivo 
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factors that affect implant function and assist in the development of an optimal, long-term 
functional tissue engineered pancreatic construct.  
  
 
6.2 Future Directions 
 
PFC Effect on Encapsulated Cell Systems 
The work in this thesis demonstrated the limited benefits of PFC incorporation in 
an encapsulated cell system.  As discussed in CHAPTER 3, there are instances at which 
changes to the construct could potentially improve the effects of PFC on cell viability and 
function.  One scenario is when PFCs are incorporated at a higher volume concentration.  
However, in our experience, it is not feasible to fabricate stable beads at a PFC 
concentration over 10 vol%.  Furthermore, the reduction of aqueous volume available to 
accommodate the cells is nonideal in vivo as larger implantation volumes will be 
required.  Since the observed results are specific to βTC-tet cells, another instance at 
which PFCs could possibly have a significant effect is when constructs contain cell types 
with a high oxygen consumption rate.  Nevertheless, our modeling studies have shown 
that even with a 6-fold increase in the consumption rate, the steady-state increase in cell 
density is only approximately 10% higher.  As we have fully addressed through 
experimental and modeling studies the limited usefulness of PFC as an oxygen carrier or 
reservoir, and discussed the limitations of constructing potentially beneficial PFC-
alginate-cell constructs, no future work can be suggested to improving PFC effects as it 




The Dual PFC Method of Monitoring  
The primary goals of establishing a noninvasive method of construct monitoring 
are to (1) understand the in vivo factors that affect construct function and elucidate the 
mechanisms of implant failure and (2) detect implant failure ahead of end physiological 
effects.  The work in this thesis proves the capability of a developed 19F NMR method to 
noninvasively measure DO within a tissue engineered pancreatic construct.  Here, we 
have taken an important step to thoroughly demonstrate that with this method, important 
correlations can be established between DO measurements and the construct’s (1) 
physiological state and (2) functionality, as reflected through insulin secretion by 
metabolically active βTC-tet cells.   
In order to arrive at the long-term goals of this method, its applicability after a 
longer period in vivo needs to be examined.  While researchers have observed intact PFC-
containing barium alginate beads for up to 18 months post-implantation [109], this has 
yet to be tested in our system.  Two issues that could potentially cause a decrease in 
NMR signal over time are the gradual loss of PFC emulsion stability and the breakage of 
the beads; both will cause the emulsion to be released from the beads and be eliminated 
by the macrophage system.  One could evaluate these potential issues through a few 
methods such as determining the changes in in vivo NMR signal intensities, 
characterizing the bead retrieval rate and the degree of bead breakage, and studying the 
progression of emulsion droplet size and size distribution over time.  Based on the 
observations made in this study, slight modifications to the developed construct may be 
necessary.  The mechanical stability of the beads can be increased by increasing the 
concentration of alginate used, reducing the emulsion concentration, or changing the 
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formulation of the cross-linking solution to form inhomogeneous beads.  Studies have 
shown that inhomogeneous alginate beads have higher long-term stability, as measured 
by a significantly lower release of encapsulated blue dextran when compared to 
homogeneous beads [48].  Also, the emulsion stability can possibly be increased by 
changing the type or concentration of surfactant used. 
In this work, barium alginate beads containing βTC-tet cells remained functional 
throughout the 16 day experimental period.  The long-term functional survival of this 
tissue implant has not been studied, although Black et al. have reported on the 
normalization of blood glucose levels in NOD mice implanted with PLL-coated calcium 
alginate beads containing βTC-tet cells for up to 8 weeks post-implantation [46].  Once 
the long-term stability of the PFC constructs is characterized, the dual PFC method can 
be used to track construct DO for a longer period of time.  Both construct DO and the 
glycemic state of initially diabetic mice should be monitored continuously until implant 
failure.  Using the established method, observations of DO measurements occurring 
around the time of implant failure, as measured by the return to hyperglycemia, might 
provide valuable information on the in vivo physiological state of the construct and assist 
in discerning between the two widely conjectured reasons for construct failure – immune 
rejection and hypoxia.  Each mechanism leading to compromised construct function is 
expected to differently affect the measured DO.  An increase in construct DO can be 
associated to a direct immunological attack causing cell death and therefore a reduction 
in the oxygen consumption.  On the other hand, a decrease in DO will most likely 
indicate a decrease in oxygen available to the cells, either due to the hypoxic implantation 
site or host cell attachment to the constructs, both of which could lead to a suppression of 
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cell functionality or even cell death.   While the in vivo environment is complex and the 
correlations might not be as straightforward, these initial speculations are based on the in 
vitro observations of construct DO profiles acquired through 19F NMR by Gross [187].   
In his study, the in vitro culturing conditions were designed to mimic an in vivo 
inflammatory response and immune rejection by changing the medium dissolved oxygen 
and inducing toxicity through the addition of puromycin, respectively.   Nevertheless, the 
validity of these speculations should be verified by checking the consistencies of the 
measured DO with the observations of the explants immediately after implant failure.  
While simultaneously studying the mechanisms of construct failure, the ability of the 
dual PFC method to detect this failure ahead of end physiological effects can also be 
tested.   The implanted cells are expected to maintain normoglycemia in the animals even 
with an increase in cell death, as the remaining fraction of viable cells is able to 
compensate for this loss by secreting more insulin.  Therefore, changes in DO are 
expected to occur before blood glucose regulation is lost.  
A drawback of the dual PFC method is its incapability to distinguish between 
oxygen consumption by the implanted βTC-tet cells and the host immune peritoneal cells.   
In our short-term study, there was no host cell attachment around the barium alginate 
beads.  However, the observed reduction in construct and peritoneal DO when compared 
to control groups could also be due to the oxygen consumption by the host peritoneal 
cells, whose number might increase after implantation over time.  Even though a 
peritoneal fluid cell count can be carried out to determine this increase, the oxygen 
consumption rate/capacity of these peritoneal cells in comparison to βTC-tet cells would 
still be uncertain.  A more robust way of clarifying this issue is to implant the constructs 
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into immunocompromised mice, such as scid or nude mice, to minimize the numbers of 
immune cells present around the constructs.  Through the use of these mice, the 
consumption of oxygen by the implanted cells and host cells could be better 
distinguished.  
 Apart from alginate-encapsulated βTC-tet cells, a variety of TEPCs using other 
cell types, construct materials, or configurations are being studied and developed.  It 
would be beneficial to examine the use of the dual PFC method in these different 
systems.  Since the PFC emulsion is not chemically bound to the matrix, this method can 
be easily adapted in other materials as long as construct stability is maintained.   An 
important next step is to monitor DO in constructs containing allogeneic or xenogenic 
islets, which are currently the most clinically relevant systems.  This is crucial as 
researchers are constantly trying to understand reasons behind the failure of encapsulated 
islet grafts so as to find ways to improve upon encapsulation techniques and methods that 
could prolong graft survival.   Making a transition to tracking DO within islet constructs 
would require that the preliminary characterization of the system be re-tested; this 
includes the effects of PFC on the encapsulated islets, the stability of the islet-containing 
beads when PFC is incorporated, and the sufficiency of the NMR signal if there is a 
reduction in implantation volumes. 
 It is also worthwhile to investigate the survival and function of these TEPCs at 
different implantation sites and different animal models using the dual PFC method.  This 
will enable the assessment of oxygen levels within the implant and its surroundings to 
determine whether a location is suitable for such implantation as it relates to construct 
oxygenation. Researchers have implanted pancreatic constructs into sites such as below 
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the kidney capsule and in the muscle, and in other animal models, particularly rats and, in 
certain cases, non-human primates [188, 189].  It will be beneficial to examine, in the 
case of a larger implant or animal model, if there will be a significant reduction in the DO 
at the implantation site.  In these instances, T1 measurements to determine DO are 
possible provided that the surface coil used is large enough to cover the area of where the 









A.1  Distribution of PFC Emulsion within the Beads 
The PFC emulsion has to be homogeneously distributed throughout the beads in 
order to accurately measure the average DO within the beads.  To determine the 
distribution of PFC, lecithin, the surfactant used to make the emulsion, was tagged with a 
fluorescently labeled fatty acid phospholipid membrane.  The lecithin tag used was 1-
Caproyl-2-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]caproyl]-sn-glycerol-3-
phosphorac-(1-glycerol) (466 excitation/536 emission).  1.0 mg of this tagged lecithin 
was added to 95 mg of the untagged lecithin and PFCE emulsion was prepared (as 
described in Section 5.4).  The alginate beads were then imaged using a fluorescent 
microscope, as shown in Figure A.1.1.  
 
Figure A.1 Distribution of PFCE emulsion throughout calcium alginate beads 
 
The green fluorescence is seen throughout the beads and is not concentrated at 
any specific region, indicating that the PFC emulsion is homogeneously distributed 
throughout the beads. 
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A.2  PFC Emulsion Stability 
 The formulation of stable PFC emulsion is important for them to be used as 
oxygen carriers or markers for monitoring, especially for long-term analyses.  Currently, 
two proposed mechanisms responsible for their aging are coalescence and molecular 
diffusion.  As both mechanisms leads to the formation of larger droplets of the emulsion, 
one of the ways to study emulsion stability is simply through droplet size measurements.  
Figure A1.2 (a) and (b) show PFC emulsion droplets before implantation and after 16 
days in vivo observed through light microscopy.  Freshly made emulsion size is 
approximately 2 µm.  The emulsion remained stable throughout the 16 days, as seen in 
the maintenance of emulsion droplet size.  
             









































Figure B.1  Metabolic activity of encapsulated βTC-tet cells under normoxic conditions.   
The number of metabolically active cells was measured as a function of time by 
alamarBlueTM and normalized to Day 1.  Measurements were performed with calcium 
alginate beads of  (a) 500 μm and (b) 1000 μm average diameter with no PFTBA, 5 vol% 
PFTBA, and 10 vol% PFTBA (n = 4 each).  The initial density of the encapsulated cells 











































































































































































Figure B.2  Stimulated insulin secretion rate (ISR) of βTC-tet cells under normoxic 
conditions.  ISR was measured over 30 min of stimulation by 16 mM glucose, normalized 
to the initial number of encapsulated βTC-tet cells, and expressed on a per unit time 
basis.  Measurements were carried out with (a) 500 μm and (b) 1000 μm average 
diameter calcium alginate beads with no PFTBA, 5 vol% PFTBA, and 10 vol% PFTBA 
(n = 4 each).  Each glucose stimulation episode followed 1 hour of exposure to basal, 0 
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Figure B.3 Glucose consumption rate (GCR) of βTC-tet cells under normoxic 
conditions.  Measurements were performed with 1000 μm average diameter calcium 
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Figure B.4  (a) Metabolic activity and (b) viability of encapsulated HepG2 cells under 
normoxic conditions.   The number of metabolically active cells was measured as a 
function of time by alamarBlueTM and normalized to Day 1 control group.  Cell viability 
was measured with trypan blue exclusion assay.  Measurements were performed with 
calcium alginate beads of 1000 μm average diameter with no PFTBA (control) and 10 
vol% PFTBA, using lecithin as the surfactant (n = 4 each).  The initial density of the 












































Figure B.5  (a) Metabolic activity of encapsulated HepG2 cells under normoxic 
conditions.   The number of metabolically active cells was measured as a function of time 
by alamarBlueTM and normalized to Day 1 control group.   Measurements were 
performed with calcium alginate beads of 1000 μm average diameter with no PFTBA 
(control) and 10 vol% PFTBA, using pluronic F-68 as the surfactant (n = 4 each).  The 




PERFUSION SYSTEM  
 
 
Bench top experiments (without the NMR system) were carried out to test the 
capability of this system to provide a well controlled environment.  This is important to 
ensure that the cells are being cultured under well optimized conditions during which 
measurements are being made.  
βTC-tet cells encapsulated at a density of 7×107 cells/ml alginate in 1000µm 
calcium alginate beads were placed in the bioreactor.  The DO of medium entering the 
bioreactor at 6.5 ml/min was kept at approximately 0.18 mM.  Figure A3.1 shows the 
temperature profile and oxygen consumption rate (OCR) of the encapsulated cells, 











Figure C.1 Time profile of temperature (right) and oxygen consumption rate (OCR) of 






















































Temperature was maintained at 37oC and the oxygen sensors were capable of tracking 
medium dissolved oxygen throughout the experimental period.   The initial OCR of the 
cells was 2.0mmol/day.109cells.  At the end of 60 hours, the cell population doubled, as 
observed in the increase in OCR.  The total viable cell number, measured at the 
beginning and end of this run using typan blue exclusion method, was also observed to 
double over this time period.  Cell survival and proliferation indicates that the perfusion 
system is able to provide a well controlled culturing environment, where cell metabolic 



















Figure D.1 Insulin secretion rate of βTC-tet cells encapsulated in APA beads, measured 
over 1 hour in basal medium (0 mM glucose, unsupplemented) and 30 minutes in 
stimulated medium (16 mM glucose, supplemented).  Explants consist of a mixture of 
cell-free and cell-containing beads; therefore data are reported from each experimental 




















Figure D.2 Insulin secretion rate of βTC-tet cells encapsulated in barium beads, 
measured over 1 hour in basal medium (0 mM glucose, unsupplemented) and 30 minutes 
in stimulated medium (16 mM glucose, supplemented).  Explants consist of a mixture of 
cell-free and cell-containing beads; therefore data are reported from each experimental 
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Figure D.3 Stimulated insulin secretion rate of βTC-tet cells encapsulated in barium 
beads, measured over 30 minutes in stimulated medium (16 mM glucose, supplemented) 
after exposure to 1 hour basal medium (0 mM glucose, unsupplemented).   Explants 
consist of a mixture of cell-free and cell-containing beads; therefore data are reported 
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